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I. Abstract 
The vagus nerve is the longest cranial nerve in the body and has innervations 
and influence on many organs, yet the mechanisms that mediate these effects 
are still to be fully understood. Electrical stimulation of the vagus nerve has been 
used to treat refractory epilepsy for over 30 years despite an incomplete 
understanding of how it produces anti-epileptic effects. More recently, vagus 
nerve stimulation (VNS) has gained huge attention after the discovery that it may 
also have therapeutic benefit in mood and inflammatory disorders. This thesis 
explored the possible mechanisms that mediate the beneficial effects of VNS with 
a particular focus on the immune system in patients with refractory epilepsy. We 
also explored other potential therapeutic effects of VNS on anxiety, fatigue and 
perceived stress as well as heart rate variation As a non-invasive biomarker for 
the associated beneficial effects. 
By 6 months post-VNS implantation, a trend in reduced perceived stress was 
observed and was independent of changes in seizure frequency, seizure severity, 
mood, age, and gender.  
In heart rate variation studies, a significant decrease in high frequency relative 
power was seen at 6 months after VNS implantation, suggesting a reduction in 
sympathetic tone. This however did not correlate with other measures tested in 
the thesis.  
Flow cytometry analysis did not identify a trend in increasing Treg frequency 
following VNS treatment. However, functional analysis suggests a reduction in 
Treg function in response to anti-CD3 antibody which mimics antigen-presenting 
cell mediated expansion of T cells. Finally, cytokine array assays identified a 
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significant reduction in the expression of BDNF, FGF-7, FGF-9, IL-1α, IL-1β, and 
MDC from plasma 3 months following VNS implantation.  
In summary, this thesis has identified novel findings which open additional 
avenues for exploring the therapeutic potential of VNS to treat stress disorders 
and its effects on Tregs for anti-inflammatory effects. 
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Chapter 1. Introduction 
 The vagus nerve 
 Anatomy 
The human body regulates many physiological processes through a plethora of 
different mechanisms to achieve homeostasis. This regulation is predominantly 
coordinated by the autonomic nervous system (ANS). Sub-divisions of the ANS 
include the sympathetic nervous system (SNS) and parasympathetic nervous 
system (PSNS) which often act with opposing effects to regulate many 
physiological functions (Mathias and Low, 2010). Traditionally, sympathetic 
output is associated with the “fight or flight” response whereas parasympathetic 
output is associated with the “rest and digest” response (Cannon, 1929, 1932). 
Both the SNS and PSNS comprise of pre-and post-ganglionic fibres but differ 
anatomically (Figure 1-1). Sympathetic ganglia are located peripherally at the 
sympathetic trunk, whereas parasympathetic ganglia are located centrally at the 
midbrain and sacral regions of the spinal cord (Mathias and Low, 2010). The 
effects of ANS are mediated by the release of noradrenaline (NA) from the SNS 
and acetylcholine (ACh) from the PSNS at postganglionic synapses. 
The vagus nerve is the major nerve of the PSNS and is the longest of the 12 
cranial nerves. It is composed of 80% afferent fibres and 20% efferent fibres 
(Foley and DuBois, 1937; George et al., 2000) with innervations to many organs 
within the body and extensive polysynaptic projections to various regions of the 
brain. The left and right vagus nerves emerge from the medulla in the midbrain 
and extend down the neck to the trunk of the body. The right vagus nerve contains 
efferents that partially supply the oesophagus and the heart whilst the left vagus 
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nerve contains efferents which partially supply the oesophagus and lungs. Both 
vagus nerves supply the stomach, duodenum, liver, pancreas, and small 
intestines (Berthoud and Neuhuber, 2000). Most vagal afferents project bilaterally 
to the nucleus tractus solitarius (NTS) which connects to many other areas of the 
brain including the thalamus, hypothalamus, the limbic system, and cerebral 
cortex (Figure 1-2) (Henry, 2002; Cheyuo et al., 2011). Translating the complex 
anatomy of the vagus nerve to determine its function is challenging. Despite these 
challenges, some functions of the vagus nerve have been uncovered but many 
remain to be determined.  
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Figure 1-1 Sympathetic and parasympathetic input to organs 
The ANS innervates many organs within the body, often with the SNS and PSNS acting on the 
same organ with opposing effects. mage taken from (Mathias and Low, 2010). 
 
 
Figure 1-2 Polysynaptic central projection of vagal afferents via the NTS 
Vagal afferents can activate many areas throughout the brain via the NTS and parabrachial 
nucleus. These areas include the hypothalamus, cerebellum, cerebral cortex, and the limbic 
system. For a full review on areas activated by vagal afferents, see review by Henry 2002. Vagal 
afferent pathway (blue arrow).  
Chapter 1. Introduction 
4 
 Function 
The vagus nerve innervates many different organs and isolating the many 
functions of this nerve is experimentally difficult since it contains both afferent and 
efferent fibres.. Various methods such as vagotomy and stimulation of the vagus 
nerve through electrical or pharmacological means have been developed to 
investigate the function of the vagus nerve in animals. Some of these functions 
have been reviewed and are summarised in Table 1-1 below. 
Table 1-1. Functions of the vagus nerve 
Reference/Review Organ Function 
(Olshansky et al., 2008) Heart Slows heart rate 
(Canning, Mori and 
Mazzone, 2006) 
Lungs Cough reflex 
(Mittal, 2016) Oesophagus Modulation of peristalsis 
(Travagli et al., 2006) Stomach Regulation of gastric motility 
(Berthoud, 2008) Liver 
Sense glucose levels 
Suppress hepatic glucose production 
(Babic et al., 2012) Pancreas 
Regulatory (excitatory and inhibitory) roles in the 
secretion of insulin and pancreatic exocrine 
(Matteoli and 
Boeckxstaens, 2013) 
Small 
intestines 
Modulating intestinal microenvironment for 
intestinal immune homeostasis 
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Heart 
One of the first identified functions of the vagus nerve is its ability to slow heart 
rate. ACh released by vagal efferents activate muscarinic type 2 receptors in the 
heart and slows heart rate (Lund et al., 1992; Olshansky et al., 2008). 
Lungs 
The cough reflex can be evoked through many mechanisms including the 
mechanical and chemical activation of vagal afferent subtypes. Each subtype of 
vagal afferent innervating the lungs have differing anatomy, physiological 
properties, and responses to various pharmacological ligands such as bradykinin, 
adenosine triphosphate (ATP), serotonin, and capsaicin (Canning, Mori and 
Mazzone, 2006). Despite the identification of vagal afferent subtypes which 
mediate the cough response, its role and mechanisms in the central nervous 
system (CNS) is complex and less defined (Canning, Mori and Mazzone, 2006). 
Oesophagus 
Most of the gastrointestinal tract is innervated by the vagus nerve. In the 
oesophagus, vagal efferents exert control over different patterns of muscle 
contraction required for peristalsis (Mittal, 2016). 
Stomach 
Vagal afferents innervating the stomach provide sensory input to the NTS and 
modulate gastric function in a reflexive manner via vagal efferents from the dorsal 
motor nucleus of the vagus (DMX). Activation of different regions of DMX can 
produce either gastric contraction (rostral/medial) or relaxation 
(caudalmedial/rostrolateral) by modulating both inhibitory and excitatory 
pathways in gastric motility (Travagli et al., 2006). 
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Liver 
Vagal afferents innervating the liver contain glucose sensors and protect against 
the detrimental effects induced by excessive energy storage in the liver 
(Berthoud, 2008). Vagal efferents may also suppress hepatic glucose production 
and may modulate the development of obesity (Berthoud, 2008). 
Pancreas 
The vagus nerve modulates both the exocrine and endocrine functions of the 
pancreas through the activation of metabotropic glutamate receptors in the 
brainstem vagal neurocircuits. This decreases both excitatory and inhibitory 
synaptic transmission to DMX neurones projecting to the pancreas  and reduces 
plasma insulin secretion while increasing pancreas exocrine secretion (Babic et 
al., 2012). 
Small intestines 
Vagal innervation to the small intestines provide a vital role in modulating immune 
homeostasis in a reflexive manner (Section 1.2.4.2). Stimulation of the vagus 
nerve activates neurones of the myenteric plexus and release of ACh to 
deactivate resident macrophages in the intestines (Matteoli and Boeckxstaens, 
2013).  
In summary, it is evident that the vagus nerve exerts control over many different 
functions within the body. Despite having identified these functions, ongoing 
studies are exploring its other functions and how manipulation of the vagus nerve 
could be used therapeutically. Over the past 30 years, electrically stimulating the 
vagus nerve has shown anti-epileptic and anti-depressive effects, with growing 
interest in exploring its therapeutic potential for other conditions.  
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 Epilepsy and the history of vagus nerve stimulation 
 Epilepsy 
Epilepsy is a common neurological disorder affecting over 70 million people 
worldwide, encompassing a very diverse range of causes (Ngugi et al., 2010) and 
manifestations (Figure 1-3) (Jette et al., 2015). In epilepsy, uncontrolled electrical 
activity of the brain causes dysfunction of various regions of the cortex, resulting 
in a seizure. Depending on the location and characteristic of the abnormal 
electrical activity, different symptoms may arise. For example, focal/partial 
seizures may affect a localised part of the brain in a single hemisphere whereas 
generalised seizures often spread within and even between hemispheres of the 
brain, leading to complex responses. In many cases, seizures can be treated with 
anti-epileptic drugs (AEDs) or surgery. However, for patients who do not respond 
to AEDs or where surgical intervention is not possible, other treatments such as 
vagus nerve stimulation (VNS) may be offered. 
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Figure 1-3 International League Against Epilepsy (ILAE) classification of seizures and 
epilepsies 
Figure adapted from Jette et al. 2015. 
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 Vagus nerve stimulation 
Corning first described mechanical carotid artery compression for limiting blood 
flow to the brain in the 19th century and was shown to be an effective abortive 
treatment for epilepsy (Corning, 1882). This was later adapted and used in 
conjunction with transcutaneous electrical nerve stimulation at the neck to 
activate vagal cardiac afferents, hypothesising that this would reduce cardiac 
output and further limit blood flow to the brain to reduce seizure frequency 
(Corning, 1884). An implantable form of VNS was later developed in animal 
models of seizures in dogs (Zabara, 1992) and monkeys (Lockard, Congdon and 
DuCharme, 1990) which were found to suppress the onset of induced seizures. 
These findings led to a clinical trial where 5 patients with refractory epilepsy were 
implanted with the VNS device and monitored for 24 weeks. Stimulation 
(intensity:1 mA, frequency: 50 Hz, pulse width: 250 μs, continuous stimulation 
pattern of on-time: 60 sec and off-time: 60 min) was applied only to the left vagus 
nerve to avoid activation of cardiac vagal fibres to induce bradycardia. This 
intervention was found to be well tolerated with only mild side effects; such as a 
tingling sensation or hoarseness whilst speaking. No noticeable changes in heart 
rate or electrocardiogram (ECG) morphology were reported (Uthman et al., 
1990). Subsequent functional magnetic resonance imaging (fMRI) studies in 
patients revealed that VNS alters blood flow to various areas of the brain and 
found that increased activity to the thalamus correlated with decreased seizures 
(Henry et al., 1999; Narayanan et al., 2002; Liu et al., 2003). Since obtaining Food 
and Drug Administration (FDA) approval in 1997, VNS has been used to treat 
refractory epilepsy in over 100,000 patients worldwide (Terry, 2009). 
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Currently, VNS devices are manufactured by Livanova (formerly Cyberonics) and 
requires surgery to implant electrode cuffs around the left cervical vagus nerve 
which is then connected to a generator placed in a subcutaneous pocket (Figure 
1-4). The patient will need to undergo surgery again to replace the device battery 
approximately every 10 years. Once implanted, the device can be remotely 
configured using a “magic wand” placed over the generator via short-ranged radio 
frequencies.  
 
Figure 1-4 Placement of VNS 
The current device is manufactured by Livanova. Figure taken from 
http://en.eu.livanova.cyberonics.com/vns-therapy/how-vns-therapy-works   
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Table 1-2 Livanova VNS device parameter settings available by manufacturer 
Stimulation Parameters Available Parameter Settings 
Output current 
0-2.0 mA in 0.125 mA steps 
2-3.5 mA in 0.25 mA steps 
Signal frequency 1, 2, 5, 10, 15, 20, 25, 30 Hz 
Pulse width 130, 250, 500, 750, 1000 μsec 
Signal ON time 7, 14, 21, 30, 60 sec 
Signal OFF time 
0.2, 0.3, 0.5, 0.8, 1.1, 1.8, 3 min and 5 to 180 min 
(5 to 60 in 5 min steps; 60 to 180 min in 30 min steps) 
Example of settings for a VNS device. Table 14 in 5.3.1 (pg 105) of VNS Therapy® System 
Physician’s Manual (US) for Model 106 
 
 Stimulation settings and efficacy 
In a meta-analysis of VNS studies comparing different doses of VNS stimulation, 
stimulation with intensities between 1.5-3 mA and frequencies between 20-30 Hz 
resulted in 31-39% of patients achieving a >50% reduction in seizure frequency. 
Stimulation with intensities and frequencies lower than this resulted in only 
13-19% patients achieving a >50% reduction in seizure frequency (Cukiert, 
2015). The studies reviewed by Cukiert compared 12 weeks baseline 
measurements against measurements up to 3 months following VNS treatment 
in children and adults (Holder, Wernicke and Tarver, 1992; Ben-Menachem et al., 
1994; Ramsay et al., 1994; Handforth et al., 1998) or adults only (The Vagus 
Nerve Stimulation Study Group, 1995). However, some studies investigated the 
efficacy of VNS for up to 9 months in children (Klinkenberg et al., 2012, 2013) 
and up to 18 months in children and adults (Handforth et al., 1998) following VNS 
treatment. 
Side effects were usually mild with patients experiencing hoarseness or voice 
alteration. The occurrence of these were dose dependent with up to 67% of 
patients receiving higher stimulation intensities (>1.5 mA and 20-30 Hz) 
compared up to 30% of patients receiving lower stimulation intensities (<1.5 mA 
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and 1-2 Hz) (Cukiert, 2015). Cukiert concluded that patients with refractory 
epilepsy above the age of 12 may benefit from VNS treatment, and although 
higher doses of stimulation results in increased efficacy, so does the likelihood of 
experiencing side effects (Cukiert, 2015).  
Due to the heterogeneity in the causes of seizures, there are currently no 
published studies with recommendations for specific stimulation parameters to 
use (Morris et al., 2013). Therefore, settings are often adjusted according to 
individual tolerance (Table 1-2) and time taken to achieve ramp up stimulation 
settings may be limited to frequency of hospital visits to adjust settings.  
Although the mechanisms for anti-epileptic effects by VNS are yet to be fully 
understood, fMRI findings studies suggests this may involve increased thalamic 
activity, as previously mentioned (Henry et al., 1999; Narayanan et al., 2002; Liu 
et al., 2003). Furthermore, electroencephalogram (EEG) recordings in patients 
with refractory epilepsy have shown that responders to VNS (n=10) who achieved 
>50% seizure reduction generally have a significantly lower level of 
synchronisation in alpha and delta bands compared to non-responders (n=9) 
(p<0.0001) (Bodin et al., 2015). This supports the hypothesis that VNS decreases 
synchronisation of EEG band waves to produce an anti-epileptic effect (Jaseja, 
2010). 
Despite an incomplete understanding of the anti-epileptic effects of VNS, other 
beneficial effects have been reported for diseases such as mood disorders 
(Section 1.3) and inflammatory disorders (Section 1.5.3). Furthermore, there is 
evidence that VNS produces cardiac effects via the hypothalamic-pituitary-
adrenal (HPA) axis, presenting as changes in heart rate variation (HRV) (Section 
1.4).  
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 Vagus Nerve Stimulation in Mood Disorders 
 Depression 
Depression is a major problem in the world affecting over 300 million people and 
is a leading cause of disability worldwide (World Health Organization, 2017). 
Despite many psychotherapeutic and pharmacological forms of treatment 
available, up to 20% of patients do not respond or become resistant to treatment 
(Burrows, Norman and Judd, 1994). Brain stimulation therapies such as 
electroconvulsive therapy and magnetic seizure induction have been used to 
treat depression with high efficacy. However, these treatments are often 
associated with adverse cognitive effects (Akhtar et al., 2016) and therefore other 
forms of neurostimulation therapies for depression have been explored, including 
VNS. 
Soon after VNS was granted FDA approval for treating refractory epilepsy, 
anecdotal clinical observations of improvements in mood emerged (Rawlins, 
1997). This led to a pilot prospective trial which monitored changes in depression 
and anxiety in adult refractory epilepsy patients following VNS (Harden et al., 
2000). Following 3 months of VNS treatment, improvements in depression were 
found when compared to baseline (P<0.05) whilst no changes in anxiety were 
observed (Harden et al., 2000). Due to the possible anti-depressive effects of 
VNS, FDA approval was granted for VNS to treat depression in 2005. 
Subsequently, this decision was met with criticism due to an inadequate number 
and poor quality of trials that supported the FDA decision to approve, as well as 
an “insufficient level of efficacy” to treat depression (O’Reardon, Cristancho and 
Peshek, 2006). 
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Many trials assessing the effects of VNS on mood have since taken place, and a 
systematic review on 18 studies observed the safety and efficacy of VNS on 
mood disorders deemed it safe (Daban et al., 2008). However, they also noted 
that although anti-depressive effects were observed, additional blinded and 
randomised trials will be required to assess its efficacy for treating refractory 
depression (Daban et al., 2008). 
Dysfunction of serotonergic and noradrenergic systems are involved in the 
pathophysiology of depression and pharmacological treatments for depression 
aim to restore these systems (Millan, 2004). VNS may exert anti-depressive 
effects through similar pathways to increase NA and serotonin signalling. For 
example, studies on VNS in rats have shown elevated extracellular levels of NA 
in the cortex and hippocampus during the stimulatory phase (Roosevelt et al., 
2006), and increased activity in serotonergic and noradrenergic brain stem nuclei 
(Dorr and Debonnel, 2006). 
Neuro-imaging studies have identified increased and decreased activities in 
various regions of the brain in treatment-resistant depression patients treated 
with VNS (Nahas et al., 2007; Kosel et al., 2011; Conway et al., 2013). However, 
the mechanism underlying the anti-depressive effect of VNS remain unknown. 
Many factors including the complexity of the disease, heterogeneity of the patient 
population, influence from multiple medications, and conflicting study findings 
have posed difficulties in deciphering the anti-depressive mechanism of VNS.  
 Anxiety 
Anxiety is a common feature in many mood disorders. Despite the wide range of 
pharmacological and psychological treatments available, many patients remain 
refractory to treatment and as such, other forms of treatment are needed (Kar 
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and Sarkar, 2016). Over the last century, various neuro-stimulation techniques 
have been developed for treating anxiety disorders (Kar and Sarkar, 2016). More 
recently however, there have been some indications from animal studies that 
VNS could treat anxiety. 
Conditioned fear response experiments in rats have demonstrated that VNS 
treatment promotes plasticity between the infralimbic medial prefrontal cortex and 
the basolateral complex of the amygdala to enhance extinction of the conditioned 
fear response (Peña et al., 2014). The authors of this study suggest its 
therapeutic potential for enhancing treatment of post-traumatic stress disorder 
(PTSD)-associated anxiety. However, there were no observed changes in anxiety 
in patients with major depression at 6 and 12 months post-VNS implantation 
according to the Beck Anxiety Inventory (Cristancho et al., 2011), and 3-months 
post-VNS implantation in refractory epilepsy patients according to the Hamilton 
Rating Scale for Anxiety (Harden et al., 2000). It remains unclear if VNS has a 
beneficial effect on anxiety in mood disorders due to the wide range of causes of 
anxiety. 
 Fatigue 
Fatigue is the lack of physical and/or mental energy perceived by an individual 
which interferes with everyday activities (Staub and Bogousslavsky, 2001). In 
particular, post-stroke fatigue is a common symptom with over 50% of stroke 
survivors (Choi-Kwon et al., 2005; Schepers et al., 2006) and fatigue is 3 times 
more common in stroke survivors than in age-matched controls (van der Werf et 
al., 2001). There are no evidence-based and effective treatments currently 
available for post-stroke fatigue (Acciarresi, Bogousslavsky and Paciaroni, 2014). 
Although some pharmacological, physical, and psychological treatments are 
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available, these tend to only alleviate the symptoms (Mead, Bernhardt and 
Kwakkel, 2012), thus there is a major need for effective post-stroke fatigue 
treatments.  
Although fatigue was reported as an adverse event in 3/14 fibromyalgia patients 
following VNS treatment (Lange et al., 2011), meta-analysis of VNS studies 
concluded that fatigue was not associated with VNS treatment (Panebianco et 
al., 2015). Much of the effects of VNS on fatigue is currently unknown, and to our 
knowledge, changes in fatigue following VNS have not been previously studied. 
 Stress 
Perceived stress affects overall health (Keller et al., 2012) and is a contributor to 
diseases such as depression (Kendler, Karkowski and Prescott, 1999; Hammen, 
2005), stroke (Booth et al., 2015), and inflammatory gastrointestinal diseases 
(Targownik et al., 2015). Despite the vast knowledge of the effects and 
mechanisms of stress, the effects of VNS on perceived stress are currently 
unknown, and no studies to our knowledge have investigated this. 
Since vagal afferents have polysynaptic projections to the hypothalamus via the 
NTS (Henry, 2002), VNS may affect the HPA axis through this mechanism to 
produce observable cardiac effects. The HPA axis is a neuroendocrine system 
known for its role in the stress response and regulation of circadian rhythm 
through the secretion of cortisol (Spencer and Deak, 2016). Interestingly, VNS 
reduces serum corticosterone levels in rats (V. De Herdt et al., 2009; 
Thrivikraman et al., 2013) and reduces elevated serum levels of cortisol in 
depressed patients to levels typically observed in healthy volunteers (O’Keane et 
al., 2005). In mood disorders including depression, the HPA axis is dysregulated 
and increased levels of cortisol may be released (Spencer and Deak, 2016). 
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Therefore, one method for studying this interaction could be monitoring changes 
in HRV.  
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 Effects of Vagus Nerve Stimulation on Heart Rate 
Variation  
HRV is the variation in the time between heart beats and may be calculated using 
a variety of methods. The Task Force of the European Society of Cardiology have 
described these time-domain, frequency-domain, and non-linear measurements 
(Appendix Table 1) (Task Force of the European Society of Cardiology the North 
American Society of Pacing Electrophysiology, 1996). 
Time-domain measurements generally refer to measurements relating to the time 
between heart beats and are the simplest to calculate with the ability to calculate 
HRV with geometric methods. Frequency-domain measurements of HRV use 
power spectral density analysis to separate a complex signal into very low (VLF), 
low (LF, 0.04-0.15 Hz), and high frequency (HF, 0.15-0.4 Hz) bands. While LF is 
an indicator of parasympathetic or vagal tone, HF is more complex and largely 
considered as an indicator for sympathetic activity. The LF/HF ratio is often taken 
as an indicator of autonomic function. Lastly, HRV may be affected by a 
combination of complex interactions and non-linear analysis have been 
suggested as a potential tool for assessing elements of this (Task Force of the 
European Society of Cardiology the North American Society of Pacing 
Electrophysiology, 1996). 
Although measures of HRV may not be directly involved with certain diseases, it 
has the potential to be used as a non-invasive surrogate biomarker for diagnosing 
or predicting disease and therapeutic outcome (Taralov, Terziyski and Kostianev, 
2015).  
Patients with epilepsy, mood disorders, and inflammatory gastrointestinal 
diseases display a reduced HRV (Pellissier et al., 2010; Ponnusamy, Marques 
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and Reuber, 2012; Sgoifo et al., 2015). Although VNS electrodes are implanted 
onto the left vagus nerve to avoid bradycardia as mentioned in Section 1.2.1, 
patients with major depression display a significantly increased root mean square 
of successive differences (RMSSD, time-domain measure of HRV) during VNS 
stimulation when compared to baseline and stimulation-free intervals (Sperling et 
al., 2010). Also, patients with refractory epilepsy display trends in decreasing in 
HF power (frequency-domain measure of HRV) following VNS treatment (Setty 
et al., 1998; Galli et al., 2003). 
Interestingly, a clinical study by Liu et al. identified pre-operative cut-off values 
for HF power to predict the outcome of VNS treatment. They found that 
responders with a >50% reduction in seizure frequency following VNS have 
similar HF power prior to VNS implantation compared to healthy volunteers. 
However, non-responders to VNS treatment have a 2-fold reduction in HF power 
prior to VNS implantation which suggests ANS dysfunction is present in these 
patients (Liu et al., 2017).  
Furthermore, ANS dysfunction was identified in patients with inflammatory 
gastrointestinal diseases as indicated by blunted vagal tone (Pellissier et al., 
2010). A 6-month pilot study by Bonaz et al. tested safety and feasibility of VNS 
in Crohn’s disease patients and found that VNS restored ANS balance (according 
to LF/HF ratio, frequency-domain measure of HRV) in patients which responded 
to treatment and achieved clinical and endoscopic remission (Bonaz et al., 2016). 
While HRV has been investigated as a predictive indicator of response to VNS 
treatment in refractory epilepsy patients, HRV biomarkers of treatment efficacy 
with VNS have not been identified for other diseases. 
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 Vagus Nerve Stimulation and Immune System 
 Background to the Immune System 
The immune system is a complex system which orchestrates the activity of many 
different immune cell types to protect the host against pathogens and facilitate 
tissue repair following an injury (Chaplin, 2010). This response requires the ability 
for the immune system to differentiate between foreign and self-tissue in a 
mechanism known as self-tolerance (Sakaguchi, 2004). This is necessary for 
avoiding damage to the host whilst combating pathogens, and failure of this may 
lead to inflammatory or autoimmune conditions. 
The immune system is formed by two different systems: the innate immune 
system and the adaptive immune system. The innate immune system is 
considered the first line of defence against pathogens. This includes: physical 
barriers (e.g. skin and mucous), and chemical barriers (e.g. soluble substances 
with acidic pH and antimicrobial properties on physical barrier surfaces). Should 
pathogens penetrate these barriers, cellular innate immune responses are 
triggered within minutes (Turvey and Broide, 2010).  
Toll-like receptors (TLR) are receptors expressed by cells of the immune system 
(such as natural killer (NK) cells, macrophages and dendritic cells) bind to a 
variety of pathogenic molecular patterns to activate the innate immune response 
(Medzhitov and Janeway, 2002). Circulating NK cells detect pathogens and 
abnormal cells via cell-cell contact and releases cytolytic granules to destroy 
them (Della Chiesa et al., 2014). Circulating monocytes mature and differentiate 
into resident macrophages or dendritic cells (Geissmann et al., 2010). Upon 
recognition of foreign antigens, resident macrophages and dendritic cells at the 
site of infection will phagocytose and degrade pathogens, decorating their cell 
Chapter 1. Introduction 
21 
surface with foreign antigen fragments. Such antigen-presenting cells (APCs) 
activate cells of the adaptive immune system to mount a stronger and targeted 
immune response (Banchereau and Steinman, 1998; Owen, Punt and Stranford, 
2013). 
While the innate immune response eliminates common pathogens within hours, 
it relies on the detection of common foreign antigens by toll-like receptors and 
may not recognise subtly different foreign antigens (Owen, Punt and Stranford, 
2013). The adaptive immune response on the other hand can detect such subtle 
differences and mount a highly specific targeted response through clonal 
selection (Burnet, 1959). During the maturation of B cells in bone marrow and T 
cells in the thymus, each cell expresses a randomly generated receptor against 
an antigen (Burnet, 1959). B cells express the receptor on their cell surface and 
produces antibodies against antigens to aid the destruction of pathogens by other 
immune cells (LeBien and Tedder, 2008). T cells express receptors against the 
antigen on their cell surface only and are classed into two major T cell types – T 
helper cells (usually expressing cluster of differentiation 4,CD4) which help 
regulate the immune response and T cytotoxic cells (usually expressing CD8) 
which eliminate foreign, infected or abnormal cells (Bevan, 2004; Laidlaw, Craft 
and Kaech, 2016). Upon encountering an antigen, specific clones of B cells or T 
cells expressing the complementary receptor will proliferate. This creates a 
greater population of cells able to recognise the antigen to destroy pathogens, 
infected, and abnormal cells which may take up to 8 days to eliminate the 
pathogen (Burnet, 1959; Owen, Punt and Stranford, 2013).  
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 Inflammation 
Inflammation is a response to infection and tissue injury characterised by heat, 
pain, redness, swelling, and loss of function. Medzhitov has previously reviewed 
its origin and physiological roles (Medzhitov, 2008). Briefly, endogenous or 
exogenous triggers, chemokines and cytokines are released and selectively 
recruit leukocytes and plasma proteins into the site of infection or injury to destroy 
pathogens and infected or damaged cells. Once these have been eliminated 
through a controlled immune response, apoptotic and necrotic cells are cleared 
and the site undergoes a resolution and repair phase (Medzhitov, 2008). 
Resolution of inflammation is traditionally mediated by neutrophil and 
macrophage associated mechanisms including: 1. chemokine depletion through 
chemokine truncation and sequestration, 2. neutrophil apoptosis, 3. apoptotic 
neutrophil clearance, 4. switching macrophage phenotype from pro-inflammatory 
to resolution phase macrophage (Ortega-Gómez, Perretti and Soehnlein, 2013). 
Additionally, regulatory T cells (Tregs) emerged as one of the key mediators in 
the resolution of inflammation.  
Firstly, Tregs are a specialised subset of immunosuppressive CD4+, CD25+, and 
forkhead box protein 3 (foxp3)-positive T cells which mediate the resolution of the 
immune response (Tao et al., 2017). This is achieved by the secretion of anti-
inflammatory molecules including interleukin (IL)-10, transforming growth factor-
beta (TGF-β), granzyme B, and perforin. Tregs may also resolve inflammation 
through cell to cell mediated mechanisms resulting in the apoptosis of myeloid 
antigen-presenting cells (such as macrophages and dendritic cells) and inhibit 
the function of T cells (Ortega-Gómez, Perretti and Soehnlein, 2013; Zeng et al., 
2015).  
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However, when the inflammatory response cannot be controlled, such is the case 
in systemic inflammation or autoimmune disorders, excessive or chronic 
inflammation leads to damage and deterioration of host tissues (Medzhitov, 
2008). Pharmacological treatments are traditionally used to suppress the immune 
response for such conditions, but emerging evidence has shown the vagus nerve 
can modulate inflammation.  
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 Anti-Inflammatory Response 
In addition to the potential interaction between the vagus nerve and HPA axis 
(Section1.4), both may also interact with the immune system. In the past 30 
years, common signalling molecules, receptors, and pathways have been 
identified in the complex interaction between the nervous, endocrine, and 
immune systems (Taub, 2008). In particular, stress causes the release of 
hormones via the activation of the HPA axis and reduces lymphocyte populations 
and function, thus leaving an impaired immune system (Webster Marketon and 
Glaser, 2008). Stress may also produce similar immunosuppressive effects to the 
immune system changes in sympathetic tone and producing changes at spleen 
and lymph nodes (Bellinger et al., 2008). Interestingly, pharmacological activation 
of the CNS via the vagus nerve produces anti-inflammatory effects (Borovikova, 
Ivanova, Nardi, et al., 2000). 
CNI-1493 is a known potent anti-inflammatory agent, and Borovikova et al. 
hypothesised its anti-inflammatory effect is exerted through CNS mechanisms. 
They investigated this through intracerebroventricular (i.c.v.) injection of  
CNI-1493 and found significantly reduced swelling in a carrageenan-induced paw 
oedema model of inflammation (Borovikova, Ivanova, Nardi, et al., 2000). 
Furthermore, vagotomy studies revealed that intact vagus nerves are required for 
the anti-inflammatory effects of CNI-1493 (Borovikova, Ivanova, Nardi, et al., 
2000). Lastly, electrical stimulation of efferent vagus nerves in vagotomised rats 
for 10 minutes before and after carrageenan-induced paw oedema were also able 
to significantly reduce inflammation (Borovikova, Ivanova, Nardi, et al., 2000). 
Although these studies showed that the vagus nerve was required to modulate 
inflammation, its underlying mechanisms remained unclear. Subsequent in vitro 
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studies by the same group revealed that activation of cholinergic receptors on 
macrophages were able to reduce the inflammatory response (Borovikova, 
Ivanova, Zhang, et al., 2000). Here, human macrophage cultures from peripheral 
blood mononuclear cells (PBMCs) and pre-conditioned with ACh. This inhibited 
the release of inflammatory cytokines (tumour necrosis factor alpha (TNF-α), IL-
1β, IL-6, and IL-18) in a dose-dependent manner following exposure to 
lipopolysaccharides (LPS) (Borovikova, Ivanova, Zhang, et al., 2000). To 
determine if this anti-inflammatory effect is influenced by the efferent vagus 
nerve, bilateral cervical vagotomy was performed in rats and the distal end of the 
vagus nerve was electrically stimulated following administration of a lethal dose 
of LPS. Rats with vagotomy alone expressed higher levels of TNF-α in serum at 
19 ng/ml  than sham vagotomy at 14 ng/ml where vagus nerves were exposed 
but not severed (p<0.05 vs sham). However, electrical stimulation of the vagus 
nerve greatly reduced serum TNF-α levels to 4 ng/ml (p<0.005 vs sham) 
(Borovikova, Ivanova, Zhang, et al., 2000). 
 The Anti-Inflammatory Reflex 
Tracey hypothesised that this anti-inflammatory effect was caused by the 
activation of vagal afferents by inflammatory mediators such as TNF-α. The vagal 
afferents would respond in a reflexive manner to activate the splanchnic nerve of 
the SNS via vagal efferents. This causes the release of ACh by cholinergic T-
cells in the spleen which activate the alpha 7 subunit of nicotinic acetylcholine 
receptors (α7nAChR) on macrophages (Figure 1-5) (Tracey, 2002; Wang et al., 
2003). Downstream pathways inhibit the transcription of nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-κB) and inhibit the expression of 
TNF-α - a key mediator of inflammation (Tracey, 2002) (Figure 1-6). VNS has 
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been shown to be anti-inflammatory and protective on a cytokine, histological, 
functional, and survival level (Table 1-3).  
Table 1-3 Effects of VNS in models of inflammation in rat 
Reference 
Model of 
inflammation 
Inflammatory 
cytokine(s) 
Histology Function Mortality 
(Borovikova, 
Ivanova, Zhang, 
et al., 2000) 
LPS 
serum and 
liver TNF-α 
NR NR NR 
(Yamakawa et 
al., 2013) 
Heat stroke 
serum 
TNF-α 
tissue 
infiltration by 
inflammatory 
cells 
NR 
+35% 
survival 
rate 
(Ay, Sorensen 
and Ay, 2011) 
tMCAO NR 
Infarct 
volume 
Neurological 
score 
NR 
(Boland et al., 
2011) 
CLP NS NS NR 
Improved 
to 0% 
mortality 
(Meregnani et 
al., 2011) 
TNBS-
induced colitis 
NS 
inflammatory 
lesions 
NR NR 
(Khodaparast et 
al., 2013) 
Microinjection-
induced focal 
ischaemia 
NR NS 
Full forelimb 
recovery by 6 
weeks 
NR 
(Levine et al., 
2014) 
CIA NS 
Joint 
damage 
scores 
Joint 
swelling 
NR 
NR = not reported, NS = no significant changes, collagen induced arthritis (CIA), caecal ligation 
and puncture (CLP), transient middle cerebral artery occlusion (tMCAO), 2,4,6-
trinitrobenzenesulfonic acid (TNBS). 
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Figure 1-5 Anti-inflammatory reflex 
Inflammation is detected by vagal afferents which activate neurones within the NTS. This 
activates neurons within the DMX and vagal afferents in a reflexive manner. Stimulation of the 
splenic nerve releases NA in the spleen, causing the release of ACh from cholinergic T cells 
(ChAT). ACh activates α7nAChR on the cell surface of macrophages in the spleen and inhibits 
TNF-α production, thereby dampening the inflammatory response. CG = Celiac ganglion.  
 = Vagal pathway, = Sympathetic pathway. 
 
 
Figure 1-6 Activation of α7nAChR on macrophages inhibits secretion of TNF-α 
Upon recognition of pathogens, activation of Toll-like receptors (TLRs) lead to the production and 
release of TNF-α via NF-κB activity. This response can be inhibited through activation of 
α7nAChR by ACh. Production of cyclic adenosine monophosphate (cAMP) in the cytoplasm are 
transported into the nucleus, mediating the transcription of cfos. AC6= Adenylate cyclase 6; IKK 
= IκB kinase; IκBα = inhibitor of κB; CREB = cAMP response element-binding protein; pCREB = 
phosphorylated CREB. Figure adapted from (Tracey, 2002).  
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 Effects of VNS in Models of Inflammation 
The anti-inflammatory effects of VNS have been studied in rat models of 
inflammation, a selection of which have been summarised in Table 1-3. As 
mentioned in the study by Borovikova et al. in Section 1.5.3.1, VNS administered 
before and after administration of LPS to induce sepsis in rats suppressed the 
expression of TNF-α in liver and serum below levels observed in sham-operated 
rats administered with LPS (p<0.05) (Borovikova, Ivanova, Zhang, et al., 2000). 
A similar reduction in TNF-α levels in serum was shown in a study by Yamakawa 
et al. deploying VNS in rats following heat stroke-induced inflammation 
(Yamakawa et al., 2013). Heat stroke is a life threatening condition whereby 
excessive heat may cause hyperthermia and result in systemic inflammation, 
multi-organ failure, and CNS dysfunction (Leon and Helwig, 2010). VNS 
administered in rats following heat stroke-induced inflammation displayed a >2-
fold reduction in serum levels of TNF-α and IL-6 up to 6 hrs after heat stroke 
compared to rats with no VNS treatment (p<0.05) (Yamakawa et al., 2013). 
Furthermore, a significantly reduced number of CD11b-positive cells (a marker of 
inflammatory cells) infiltrated into tissues under immunohistological examination 
of spleen (8-fold reduction) and lung 
(2-fold reduction) tissues in the VNS group compared to the no-VNS group 
(p<0.05) (Yamakawa et al., 2013). They reported a significantly higher survival 
rate of 61% in mice treated with VNS compared to 26% in the no VNS stimulation 
group (n=23/group, p=0.016) (Yamakawa et al., 2013). 
In another model of inflammation, Boland et al. used caecal ligation and puncture 
(CLP) to induce peritonitis, VNS was administered 4 hrs later for 20 mins (15 V, 
5 Hz, 2 ms). All rats in the VNS group had survived whilst the group which did not 
receive VNS treatment had a survival rate of 71% (Boland et al., 2011). 
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The effects of VNS were studied in a rat model of inflammatory bowel disease by 
Meregnani et al. whereby colitis was induced through insertion of a cannula into 
the colon and administering 2,4,6-trinitrobenzenesulfonic acid (TNBS). VNS 
treatment started 1 hour prior to induction of colitis with a total of 3 hours 
stimulation a day for 5 days (1 mA, 5 Hz, 0.5 ms, on time 10 s, off time 90 s, 
continuous cycle). Histological examination of colon tissue at the end of the study 
revealed that VNS had visibly reduced inflammation. No significant changes in 
the expression of TNF-α, IL-1β, Intercellular Adhesion Molecule 1 (ICAM1), and 
IL-6 messenger ribonucleic acid (mRNA) from colonic tissue samples were 
associated with VNS treatment (Meregnani et al., 2011). 
It is evident that VNS administration is capable of attenuating inflammation at 
these levels and reducing mortality under various models of inflammation in rats. 
Translating these findings into a clinical setting is a potentially invaluable benefit 
which may reduce inflammation and improve quality of life.  
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 Therapeutic potential of VNS in Inflammatory 
Diseases 
Clinical studies using VNS have displayed similar anti-inflammatory effects seen 
in studies deploying VNS in animal models of inflammation (Table 1-3) and show 
promise for its use to treat a variety of inflammatory diseases in humans. Here, 
we focus on the therapeutic applications of VNS in rheumatoid arthritis (RA), 
stroke, and inflammatory gastrointestinal diseases. 
Rheumatoid arthritis 
RA is an autoimmune disease characterised by pain, chronic synovial 
inflammation (synovitis), excessive production of inflammatory cytokines, and 
hyperplasia at joints leading to, deterioration of cartilage and bone, and ultimately 
immobility (McInnes and Schett, 2011). The majority of therapies for treating RA 
have primarily focused on inhibiting TNF-α function (McInnes and Schett, 2011). 
Interestingly, VNS administered in rats with collagen induced arthritis (CIA) 
showed attenuated TNF-α release and reduced swelling (Levine et al., 2014) 
(Table 1-3). Furthermore, functional assays assessing cytokine production from 
7 epilepsy patients with VNS in response to endotoxin revealed a >2-fold 
reduction in TNF-α, IL-6 and IL-1β levels compared to pre-surgery levels (p<0.05) 
(Koopman et al., 2016). Following these findings, the therapeutic efficacy of VNS 
was assessed in a pilot study with RA patients (Andersson and Tracey, 2012). 
In one of the first RA patients to be implanted with the device, joint pain was 
alleviated and serum levels of C-reactive protein (CRP) had reduced to levels 
seen in healthy volunteers after 8 weeks of VNS treatment (Andersson and 
Tracey, 2012). Following this, a multi-centre clinical trial implanted 18 RA patients 
and which provided a single 60 s stimulation (0.25-2.0 mA, 10 Hz, 250 μs) 1-4 
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times a day. This led to significantly reduced levels of TNF-α, IL-6, and CRP in 
serum compared pre-implantation levels (p<0.05). However, when the stimulator 
was switched off, the levels of these molecules would increase again, thereby 
demonstrating treatment of RA with VNS requires a daily stimulation (Koopman 
et al., 2016). 
Stroke 
Stroke is a leading cause of disability worldwide, and the initial cell death and is 
followed by a secondary inflammatory phase which causes further cell death to 
areas surrounding the site of ischaemia (Wang, Tang and Yenari, 2007). All 
clinical trials of pharmacological treatments for stroke arising from rodent studies 
have failed, and the only approved treatment of stroke is tissue plasminogen 
activator (t-PA) which has a narrow window for therapeutic benefit. Since VNS 
attenuates inflammation (Borovikova, Ivanova, Zhang, et al., 2000; Yamakawa et 
al., 2013) it is predicted that VNS may limit inflammation following stroke. In 
preclinical studies (Table 1-3), VNS administered 30 mins after transient middle 
cerebral artery occlusion (tMCAO) in rats had significantly reduced infarct volume 
by approximately 50% compared to the no VNS group (p<0.05) (Ay, Sorensen 
and Ay, 2011). In addition to this, neurological scores assessing motor ability had 
significantly improved 1 to 3 days following tMCAO in the VNS group compared 
to a control group receiving no VNS treatment following tMCAO (p<0.05) (Ay, 
Sorensen and Ay, 2011). 
Limb impairment following stroke is common outcome found in >80% of stroke 
survivors (Nakayama et al., 1994) and treatments for recovering arm function is 
one of the key research priorities relating to life after stroke (Pollock et al., 2012). 
Interestingly, VNS paired with forelimb rehabilitation after microinjection-induced 
focal ischaemia in rats displayed an improved rate of rehabilitation (Khodaparast 
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et al., 2013) (Table 1-3). Rats were first trained to perform a pulling task upon 
which triggers an automated pellet dispenser to deliver a sucrose pellet when the 
pulling force exceeded 120 g. Focal ischaemia was induced by microinjecting 
endothelin-1 at the motor cortex and VNS was delivered within 30 ms of 
exceeding 120 g pulling threshold. Paired stimulation of VNS to a successful pull 
showed significantly improved rate of forelimb recovery to pre-ischaemic levels 
6 weeks following focal ischaemia (VNS group n=6, no VNS group n=9; 
successful pull rate in VNS group = 88% vs no VNS = 63%, p<0.05; average peak 
pull force in VNS group = 105% of pre-ischaemic force vs no VNS = 57% of pre-
ischaemic force, p<0.05) (Khodaparast et al., 2013).  
These findings in animal studies suggest that VNS paired to forelimb movement 
may enhance forelimb rehabilitation following a stroke, and indeed VNS-paired 
rehabilitation significantly improved motor function in a 6-week pilot study with 
stroke patients (Fugl-Meyer assessment score difference from baseline:  
VNS= +9.6 (n=9) vs rehabilitation only = +3.0 (n=10), p=0.038) (Dawson et al., 
2016). 
Inflammatory gastrointestinal diseases 
The vagus nerve innervates the majority of the gastrointestinal (GI) tract from the 
oesophagus to the small intestines (Berthoud and Neuhuber, 2000) (Section 
1.1.1) and forms part of the brain-gut axis. Interactions in the brain-gut axis 
involves bi-directional communication between: the enteric nervous system, 
peripheral and central nervous systems, HPA axis, and gut walls (Collins and 
Bercik, 2009) to modulate aspects of behaviour and gut function in response to 
external and bodily demands (Mayer, Tillisch and Gupta, 2015).  
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Autonomic dysfunction, indicated by a significantly blunted vagal tone, has been 
observed in patients with inflammatory bowel disease (Pellissier et al., 2010). 
Furthermore, TNF-α is highly expressed in patients with Crohn’s disease 
(Pellissier et al., 2014). VNS has been suggested as a treatment for inflammatory 
gastrointestinal diseases to restore the vagal tone and reduce inflammation. 
Indeed, a rat study discussed above (Section 1.5.3.2) found administration of 
VNS had attenuated inflammation following induction of colitis (Meregnani et al., 
2011). 
Furthermore, a 6-month pilot study performed by Bonaz et al. studied the 
therapeutic effects of VNS in 7 patients with Crohn’s disease (Bonaz et al., 2016). 
2 patients withdrew from the study 3 months following VNS treatment due to 
worsening of disease, however, the remaining 5 patients displayed improvements 
in Crohn’s disease activity indices (4 patients in clinical remission for disease 
activity at 6 months) and Crohn’s disease endoscopic index of severity (5 patients 
in endoscopic remission at 6 months) (Bonaz et al., 2016).  
In summary, despite an incomplete understanding of the mechanisms in VNS, it 
is evident that VNS produces an anti-inflammatory effect which can benefit 
conditions such as rheumatoid arthritis, stroke, and inflammatory GI diseases. 
Findings in animals have been directly translatable to clinical trials, and advances 
in understanding the pathways responsible for the anti-inflammatory effect by 
VNS will allow identification of biomarkers such as HRV which will aid the 
monitoring and refinement of treatment efficacy in the future. 
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 Aims 
Although much has been deciphered about the physiological and pathological 
roles of the vagus nerve, much remains unknown. There is a major need for a 
better understanding of the mechanistic pathways which mediate the effects of 
VNS and whether VNS could also be beneficial in other disabling conditions like 
fatigue, stress, and anxiety. A better understanding of how VNS influences HRV 
is also needed and whether this indicates improvement in health and treatment 
efficacy. Moreover, the effect of VNS on anti-inflammatory cells such as Tregs 
and pro- (e.g. TNF-α, IL-6, IL-1) and anti-inflammatory cytokines (e.g. TGF-β,  
IL-10) also need to be determined. 
Determining the changes in immune cells, cytokines, and HRV after VNS could 
lead to the identification of key biomarkers that could aid the optimisation of VNS 
therapy such as optimum stimulation settings to attain a therapeutic response in 
individual patients. Moreover, biomarkers could also serve as surrogate 
endpoints in clinical trials, thus potentially reducing the number of patients 
needed. 
In the current study, we recruited patients with refractory epilepsy who were 
referred to Royal Hallamshire Hospital (RHH) for VNS implantation. While this is 
not an ideal patient group for our study since many patients have structural brain 
abnormalities, learning disabilities, co-morbidities, and are taking many 
medications, insertion of a VNS device which requires invasive surgery could not 
be ethically justified in normal individuals which arguably would be the ‘ideal’ 
group to explore mechanistic pathways. We collected samples before and up to 
6 months after VNS implantation.  
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The primary aims of this study were: 
Aim 1: To determine the effect of VNS on other unexplored mood disorders 
such as anxiety, fatigue and stress 
Hypothesis: VNS will have beneficial effects on anxiety, fatigue, and stress. 
Aim 2: To determine the effects of VNS on HRV 
Hypothesis: VNS will enhance HRV and this will correlate with the beneficial 
effects of VNS. 
Aim 3: To determine changes in anti-inflammatory cell frequency and 
function and in pro and anti-inflammatory cytokines after VNS 
Hypothesis: VNS will alter cell frequencies and expression of cytokines in blood 
to promote immune tolerance. Furthermore, VNS will enhance the functional 
capacity of Tregs to promote immune tolerance. 
In summary, this is the first study to observe the psychological, cardiac, and 
neuroimmune effects of VNS simultaneously. Findings from this study will aid the 
understanding of the complex function of the vagus nerve and the mechanisms 
that mediate VNS. Furthermore, these findings may allow the identification of 
biomarkers to help track or determine effectiveness of VNS therapy, to aid 
optimisation of VNS settings/regime, and suggest other therapeutic uses of VNS. 
  
Chapter 1. Introduction 
36 
 
 
Chapter 2. Materials and Methods 
37 
Chapter 2. Materials and Methods 
 Materials 
 Reagents 
Table 2-1 Table of materials 
Description Manufacturer 
Catalogue 
number 
Anti-Mouse Ig, κ/Negative Control Compensation 
Particles Set 
BD Bioscience 552843 
Anti-Rat Ig, κ/Negative Control Compensation 
Particles Set 
BD Bioscience 552844 
Cell Proliferation Dye eFluor® 450  eBioscience 65-0842-85 
Foxp3 Transcription factor staining buffer set eBioscience 00-5523-00 
Glass Sodium Heparin Plasma tube BD Bioscience VS368480 
Human Cytokine Array C5 RayBiotech AAH-CYT-5-4 
Lymphocyte separation medium 1.077 Lonza LZ17-829F 
RPMI 1640 + L-glutamine cell culture media Lonza LZBE12-702F 
Staphylococcal enterotoxin B (SEB) from 
Staphylococcus aureus 
Sigma S4881-1MG 
UV cell viability dye Life technologies L-23105 
 
Table 2-2 Table of antibodies 
Antibody/Isotype control Manufacturer 
Catalogue 
number 
Mouse anti-human CD4:FITC eBioscience 11-0048-42 
Mouse anti-human CD25:PE eBioscience 12-0259-42 
Mouse anti-human CD8a APC-eFluor780 eBioscience 47-0088-41 
Mouse anti-human CD14:PerCP-Cy5.5 eBioscience 45-0149-41 
Mouse anti-human CD19:PE-Cy7 eBioscience 25-0199-41 
Rat anti-human Foxp3:APC eBioscience 17-4776-42 
Mouse IgG2b K Isotype Control FITC eBioscience 11-4732-42 
Mouse IgG1 K Isotype Control PE eBioscience 12-4714-42 
Mouse IgG1 K Isotype Control APC-eFluor780 eBioscience 47-4714-80 
Mouse IgG1 K Isotype Control PerCP-Cy5.5 eBioscience 45-4714-80 
Mouse IgG1 K Isotype Control PE-Cy7 eBioscience 25-4714-80 
Rat IgG2a K Isotype Control APC eBioscience 17-4321-81 
Anti-human CD3 Functional Grade Purified 
(aCD3) 
eBioscience 16-0039-81 
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 Software 
Microsoft excel, SPSS (version 22), and Graphpad Prism 7 were used for 
statistical analysis and creating graphical outputs. ECG data were uploaded 
using the FirstBeat uploader and analysed using Kubios HRV analyser. Flow 
cytometry data were analysed using FlowJo (version 7.6.5). Figures were created 
in Adobe Illustrator. 
 Questionnaires 
Table 2-3. List of questionnaires and purpose 
Questionnaire Purpose Reference 
Liverpool Seizure Severity 
Scale (LSSS) 
Seizure number and severity for the 
past 4 weeks. 
(Scott-Lennox et al., 
2001) 
Neurological Disorders 
Depression Inventory for 
Epilepsy (NDDI-E) 
Rapid screening of major depression 
in patients with epilepsy over the past 
2 weeks. Patients with a score of >15 
are likely to suffer from major 
depression. 
(Gilliam et al., 2006) 
General Anxiety Disorder 
assessment (GAD-7) 
Screening tool and severity measure 
for generalised anxiety disorder over 
the past 2 weeks. 
(Spitzer et al., 2006) 
Fatigue Assessment 
Scale (FAS) 
Measure of chronic fatigue.  
(Michielsen, De Vries 
and Van Heck, 2003) 
Perceived Stress Scale 
(PSS) 
Measure of perceived stress in the 
past month. 
(Cohen, Kamarck and 
Mermelstein, 1983) 
Note: For full copies of questionnaires, see Appendix Section 8.4 
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 Methods 
 
Figure 2-1 Summary of method workflow 
At each visit, patients will complete a series of questionnaires, undergo a 5-minute ECG, and 
provide a blood sample. 
 
 Ethics 
An Independent Scientific Review (ISR) was performed prior to the submission 
of ethics. Ethical approval was granted by the ethics committee at Sheffield 
Teaching Hospitals (STH) Research department for RHH, Sheffield, England and 
the National Research Ethics Service (NRES) committee North West – Haydock 
(14/NW/1221). See Appendix Section 8.1 for approvals and Appendix Section 
8.2 for application and supporting documents for ethics approval including 
protocol, information sheets, and consent form templates. All samples were 
assigned a unique identifier number and anonymised at the point of collection. 
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 Recruitment 
Healthy volunteers were approached at the University of Sheffield, and refractory 
epilepsy patients were identified and approached at RHH in Sheffield. Both 
healthy volunteers and patients were screened according to the inclusion and 
exclusion criteria below: 
The inclusion criteria are as follows:  
• Participants must be above 18 years or older 
• Participants without a history of autoimmune disorders 
• Participants without a history of long term immunomodulatory treatment  
The exclusion criteria are as follows: 
• Participants under the age of 18 years 
• Participants with a history of autoimmune disorders 
• Participants who have previously received immunomodulatory treatment 
• Who already have an electrical implant such as a pacemaker 
• Already taking part in another intervention study 
• Patients that have experienced seizure(s) 48 hours prior or presenting with 
signs of clinical infection on the day of blood sampling may be asked to 
have the routine consultation and sampling postponed as a measure of 
control for the study where possible. 
Healthy volunteers and patients fulfilling the criteria were given information 
sheets regarding the study and a formal written consent was obtained for subjects 
recruited into the study. 
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 Surgery and Follow-up 
A detailed protocol describing the implantation procedure can be found in section 
12 of the VNS Therapy System Physician's Manual (version 5.17, 
https://us.livanova.cyberonics.com/healthcare-professionals/resources/product-
training accessed 03/07/2017). Briefly, a small incision is made along the left side 
of the neck to expose the left vagus nerve, and another incision is made below 
the collar bone in the chest or arm pit, forming a subcutaneous pocket to house 
the pulse generator. A lead is tunnelled from the incision at the neck to the pocket, 
and the electrodes are attached to the left vagus nerve. The lead is then 
connected to the pulse generator and placed inside the subcutaneous pocket. 
The generator is switched on immediately to test the device, and stimulation 
intensity is gradually increased according to patient’s tolerance at each follow-up 
appointment. 
 Sample Collection 
Patients completed questionnaires, ECGs were recorded, and blood samples 
were taken prior to VNS implantation (at pre-operation assessment or on the day 
of the surgery) and at 3- and 6-month follow-up appointments. 
Questionnaires 
Validated questionnaires were self-administered or assisted by the next of kin at 
each visit. The questionnaires administered included are listed in Table 2-3. 
These were used to monitor seizure frequency and severity (LSSS), 
mood/depression (NDDI-E), general anxiety (GAD-7), fatigue (FAS), and 
perceived stress (PSS). Questionnaire scores were deduced according to scoring 
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methods described in their respective published studies (Table 2-3 and 
Appendix Section 8.4) 
ECG 
A 5-minute single-lead ECG (FirstBeat Bodyguard 2) recording was performed at 
each visit. Briefly, patients were laid down in a supine position and asked to 
remain still for the duration of the recording. Electrodes were attached to the right 
collarbone and left side of the patient according to manufacturer’s protocol 
(Figure 2-2). The device automatically detects electrical discharge and records 
heart beats. 
Blood sampling 
Approximately 20 ml of blood was drawn from healthy volunteers and patients 
from the cubital vein into vacutainers containing lithium heparin anticoagulant. 
Samples were mixed well by gently inverting the vacutainers several times to 
ensure thorough mixing of blood with heparin.  
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Figure 2-2 Firstbeat Bodyguard 2 manufacturer's protocol 
 
 Deducing Measures of HRV 
5-minute single lead ECG recordings were imported into Kubios HRV software 
and a 3-minute artefact-free interval was selected for automated analysis 
(Appendix Figure 1 for full output of analysis). The key measures of HRV 
selected for analysis of this study and their descriptions are outlined in Table 2-4. 
In addition to this, Toichia and colleagues described non-linear methods of 
calculating sympathetic and vagal activity using the formulae below (Toichi et al., 
1997): 
(1) Cardiac sympathetic index (CSI)  =  SD1 ×  SD2  
(2) Cardiac vagal index (CVI) = log10[SD1 ×  SD2]  
These nonlinear measures of sympathetic and vagal indices were also included 
in the analysis of the effects of VNS on HRV. 
  
Chapter 2. Materials and Methods 
44 
The key measures of HRV observed in this study include: 
Table 2-4 Key HRV measures observed 
HRV parameter Description 
Mean HR (bpm) Mean of heart rate in beats per minute 
STD HR (bpm) Standard deviation of heart rate in beats per minute 
HRV Triangular Index 
The integral of the RR interval (time between beats) histogram 
divided by the height of the histogram as a geometric measure of 
overall heart rate variation 
LF Relative Power (%) 
Relative power (signal energy) of the low-frequency band as a 
percentage of total HRV power. 
HF Relative Power (%) 
Relative power (signal energy) of the high-frequency band as a 
percentage of total HRV power. 
LF/HF Ratio 
Ratio between LF and HF, a commonly used measure of autonomic 
tone. A higher LF to HF ratio suggests greater X activity whereas a 
lower LF to HF ratio suggests greater X activity. 
CSI A non-linear measure of sympathetic activity  
CVI A non-linear measure of vagal activity 
References: (Task Force of the European Society of Cardiology the North American Society of 
Pacing Electrophysiology, 1996; Toichi et al., 1997) 
 
Outputted measures of HRV were transferred into SPSS and Graphpad for 
statistical analysis. 
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 Isolation of Peripheral Blood Mononuclear Cells 
(PBMCs) and Plasma 
Heparinised blood was diluted with sterile phosphate buffered saline (PBS) in a 
1:1 ratio. 20 ml of diluted whole blood was carefully layered on top of 10 ml 
lymphocyte separation medium (LSM) as per the manufacturer’s protocol. 
Samples were centrifuged at 400 x g for 40 minutes with soft start and no brake 
to create a density gradient with distinct plasma, white buffer coat, LSM, and red 
blood cell layers (Figure 2-3). 
Fresh diluted plasma was used fresh for cytokine array assays (Section 2.2.10). 
The white buffy coat layer containing PBMCs was washed with approximately 30 
ml sterile PBS and centrifuged at 600 x g for 12 minutes. The supernatant was 
discarded, and the cell pellet was resuspended and washed with 15 ml sterile 
PBS for two further washes at 600 x g for 5 minutes. The remaining PBMCs pellet 
was resuspended in 1 ml RMPI-1640 media containing 20% FBS. A 5 μl sample 
of PBMCs was added to 95 μl of trypan blue to estimate the number of viable live 
cells in the sample. This was estimated using a haemocytometer according to the 
figure and equation below (Figure 2-4). PBMCs were diluted with media for a 
final working concentration of 1x107 cells/ml for subsequent assays. 
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Figure 2-3 PBMC isolation 
Centrifugation of diluted whole blood on LSM produces a density gradient which separates the 
components of blood into plasma, a white buffy coat (containing PBMCs) and red blood cells.  
 
 
Figure 2-4 Method for estimating number of viable cells using a haemocytometer 
Yellow highlighted squares indicate the squares where viable cells were counted. The sum of 
cells in A-D were taken as the average number of cells to estimate number of cells in the sample 
using the equation above. 
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 Immunocytochemistry (ICC) 
1x106 PBMCs were aliquoted into separate tubes and washed twice with 1 ml 
PBS supplemented with 0.1% Bovine Serum Albumin (BSA) (5 mins at 400 x g 
and 4°C). Samples were subsequently incubated with ultraviolet (UV) cell viability 
dye and flow cytometry antibodies, or isotypes controls (Figure 2-5). Flow 
cytometry beads were incubated with individual fluorescent antibodies for 
calculating the compensation matrix during analysis. 
Briefly, PBMCs were incubated with fluorescent antibodies targeting extracellular 
CD4, CD25, CD8, CD14, and CD19 in addition to UV cell viability dye for 1 hour 
at 4°C in the dark. Since foxp3 is expressed intracellularly, PBMCs were 
subsequently fixed and permeabilised for 45 minutes at 4°C in the dark then 
washed 2 times. Lastly, cells were incubated with anti-foxp3 fluorescent antibody 
for 35 minutes at 4°C in the dark and washed a further 2 times before being 
analysed using the flow cytometer. 
 
Figure 2-5 Immunocytochemistry protocol 
Samples were washed with 1 ml PBS supplemented with 0.1% Bovine Serum Albumin (BSA) and 
centrifuged for 5 mins at 400 x g and 4°C. Incubations steps were performed at 4°C in the dark. 
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 Functional Assay 
Following PBMC isolation, cells were stained using cell proliferation dye eFluor 
450 according to manufacturer’s protocol. It is important to note that this dye is 
not harmful to the cell and does not affect cell processes according to the 
manufacturer. Briefly, 1 x 107 cells were washed with sterile 4 ml PBS and 
incubated with 1 ml of dye for 20 mins in the dark at room temperature. Samples 
were blocked with 4 ml media for 5 mins on ice, and subsequently washed 3 times 
with 5 ml media at room temperature. Supernatants were discarded and cell 
pellets containing PBMCs were resuspended with media to make a working 
concentration of 1 x 107 cells/ml. 
1 x 106 PBMCs were aliquoted into wells on a 48-well plate and incubated at 37°C 
and 5% CO2 for 96 hours under three different conditions: (1) unstimulated control 
with only media (2) wells pre-coated with 250 ng anti-human CD3 antibody 
(aCD3) to mimic activation by antigen presenting cell (APC) (3) media containing 
400 ng Staphylococcal enterotoxin B (SEB) to activate TLR pathways. Unstained 
PBMCs and PBMCs stained with the proliferation dye were also incubated with 
only cell culture media as controls for flow cytometry analysis. Following 
incubation, cells were resuspended and centrifuged for 5 minutes at 400 x g and 
4°C, following the ICC staining protocol outlined above (Figure 2-5). 
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 FlowJo Analysis 
Flow cytometry data was analysed using FlowJo version 7.6.5 Compensation 
beads and sample controls (unstained, isotype, UV-only, and proliferation dye-
only) were used to calculate the compensation matrix required for compensation.   
In both cases, monocytes (Figure 2-6A) and lymphocytes (Figure 2-6B) were 
gated according to size (forward scatter) and granularity (side scatter) from an 
unstained control sample and analysed separately to reduce background noise 
in data arising from the monocyte population. In Figure 2-6A, the monocyte 
population was interrogated according to size and area of cells and only single 
cells were gated. This reduces the likelihood of false positives arising from 
doublets passing through the flow cytometer. Within the single cell population, 
viable cells were gated according to UV fluorescence. Finally, viable cells 
expressing high expression of CD14 were recorded as monocytes. Likewise, in 
Figure 2-6B, lymphocytes were gated in a similar way to monocytes above but 
except the high expression of CD4, CD25, CD8a, CD19 were recorded instead. 
Additionally, CD4+ and CD25+ viable cells were gated, and foxp3+ cells within 
this population were gated as Tregs. Cell populations were represented as 
percentage of live (viable) cells from either the monocyte gate or lymphocyte 
gate. 
Proliferation is measured using FlowJo’s proliferation platform tool (Figure 2-6C). 
Briefly, a built-in algorithm creates and fits a number of peaks from a histogram 
of fluorescence intensity. The number of peaks were determined according to the 
lowest root mean squared (RMS) value outputted by the algorithm as lower 
values indicate a more accurate model (Roederer, 2011). Control samples 
without in vitro stimulation were used to calibrate the fluorescence intensity for 
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the undivided cells peak in all groups within an assay. The level of proliferation is 
quantified by the: 
Division index – The average number of divisions a cell has undergone within a 
sample including non-dividing cells, and the;  
Proliferation index – The average number of divisions a cell has undergone 
within a sample excluding non-dividing cells. 
The division index is a measure of overall function of the sample, whereas the 
proliferation index is a measure of the function of responding cells only.  
Chapter 2. Materials and Methods 
51 
 
Figure 2-6 Flow cytometry gating strategy and analysis 
Gating strategies for (A) monocytes and (B) lymphocytes. (C) Example of cell division histograms 
for analysing cell proliferation via FlowJo’s proliferation platform. FSC = Forward scatter (FSC-A= 
by cell Area, FSC-H = by cell Height), SSC-A = Side scatter by cell area, Red peaks = undivided 
cells, purple peaks = divided cells. 
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 Cytokine Array 
Ray Biotech cytokine arrays were used according to manufacturer’s protocol to 
observe semi-quantitative changes in the relative expression of 80 inflammatory 
cytokines. Briefly, membranes were blocked with the supplied blocking buffer for 
30 mins and incubated with human plasma overnight at 4°C. Membranes were 
washed using supplied washing buffers and incubated with an antibody cocktail 
for 2 hours, these were washed and incubated with horseradish peroxidase 
(HRP)-Streptavidin for a further 2 hours. Following a final wash, enhanced 
chemiluminescence reagents were added onto the membranes and imaged 
using the intelli-chemi setting on the G-box to observe relative expression of 
cytokines in the sample. Signal intensity of cytokines were expressed as a 
percentage relative to the average of positive controls and the average of 
negative controls were used for background correction. 
 Statistics 
In this exploratory study,one-way analysis of variance (ANOVA) with repeated 
measures and Tukey correction was used to detect differences in the observed 
parameters between timepoints. Paired T-tests were used to compare 
differences between two timepoints in patients with an incomplete set of data. 
Furthermore, paired T tests with Bonferroni correction was used for the analysis 
of cytokine arrays. 
Power analysis was performed using G*power 3.1. The mean of difference and 
standard deviation of difference were used to calculate the effect size. An α error 
probability was set to 0.05, and power (1-β error probability) was set to 0.80. 
These parameters were used perform a two-tailed matched-pair T test to 
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calculate the sample size required to detect a significant change in variables 
between two timepoints. 
Chapter 2. Materials and Methods 
54 
Chapter 3. Mood 
55 
Chapter 3. Mood 
 Introduction 
Since VNS was granted FDA approval for use in refractory epilepsy, beneficial 
changes in mood have been observed (Rawlins, 1997; Harden et al., 2000; 
Daban et al., 2008). Although its anti-depressive efficacy remains to be fully 
evaluated (O’Reardon, Cristancho and Peshek, 2006), others have explored its 
mechanism and effects on mood in rats (Peña et al., 2014). Peña and colleagues 
suggested VNS may also benefit other mood disorders such as anxiety, but the 
effects of VNS on anxiety were unclear when studied in humans (Harden et al., 
2000). 
Fatigue has been reported as an adverse event following VNS treatment in one 
study (Lange et al., 2011), however it was not significantly associated with the 
treatment (Panebianco et al., 2015). The effects of VNS on fatigue are currently 
unknown, and no studies to our knowledge have studied the changes in fatigue 
before and after VNS treatment. 
Perceived stress is a contributor to depression (Kendler, Karkowski and Prescott, 
1999; Hammen, 2005) and activates the HPA-axis to release stress hormones to 
produce physiological stress responses (Herman et al., 2012). Since vagal nerve 
afferents innervates the NTS which has connections to the hypothalamus (Henry, 
2002), VNS may alter the stress response and perceived stress. To our 
knowledge, no studies have investigated the effects of VNS on perceived stress.  
In this study, we explore other side effects of VNS on mood; focusing on its effects 
on anxiety, fatigue, and perceived stress. Validated questionnaires were 
administered to patients to assess changes in seizure severity and frequency 
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(Scott-Lennox et al., 2001), depression (Gilliam et al., 2006), anxiety (Spitzer et 
al., 2006), fatigue (Michielsen, De Vries and Van Heck, 2003), and perceived 
stress (Cohen, Kamarck and Mermelstein, 1983). These short questionnaires 
were chosen to encourage patient adherence to the study and act as a screening 
tool to identify aspects of mood to investigate in future studies. 
 
Aim 1: To determine the effect of VNS on other unexplored mood disorders 
such as anxiety, fatigue and stress 
Hypothesis: VNS will have beneficial effects on anxiety, fatigue, and stress. 
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 General Methodology 
Patients with refractory epilepsy were asked to complete a series of short 
questionnaires prior to VNS implantations and at their 3- and 6-month follow up 
appointments. Questionnaires administered include: Liverpool seizure severity 
scale (LSSS, 100-point scale), Neurological disease depression inventory for 
epilepsy (NDDI-E, 24-point scale), General Anxiety Disorder Assessment (GAD-
7, 21-point scale), Fatigue Assessment Scale (FAS, 50-point scale), and 
Perceived Stress Scale (PSS, 40-point scale) (Appendix Section 8.1). 
One-way ANOVAs with repeated measures and Tukey correction were used to 
analyse full sets of data (excluded data from patients 007 and 010 where data for 
6M was not available). Separate pair-wise T test comparisons with Bonferroni 
correction were used to test for differences in questionnaire scores between pre-
stimulation (PS) and 3-months including data from patients 007 and 010.  
Questionnaire scores were compared against each other to investigate potential 
trends in seizures and mood following VNS implantation. Additionally, changes in 
questionnaire scores were compared to differences in age and gender. 
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 Results 
 Recruitment 
 
Figure 3-1 Summary of recruitment for assessing effects of VNS on mood 
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Table 3-1 Summary of recruited patients for assessing effects of VNS on mood 
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001 39 F ✔* 105 1.25 20 250 30 5 
004 72 F ✔ 106 1.00 20 250 30 5 
007 42 F 3M* 106 1.00 15 250 30 5 
010 46 F 3M 106 1.00 25 250 30 5 
011 22 M ✔ 106 1.13 20 250 30 1.8 
013 34 M ✔ 105 1.25 20 250 30 3 
014 46 F ✔ 105 1.00 20 250 30 1.8 
015 23 M ✔ 105 1.75 25 250 30 1.8 
016 25 M ✔ 105 0.75 30 250 30 3 
020 21 M ✔ 105 1.75 25 250 30 1.8 
022 42 F ✔ 105 1.50 20 250 30 3 
023 53 F ✔ 105 1.25 20 250 30 1.8 
024 22 M ✔ 105 1.50 20 250 30 1.8 
✔=full set of data available,  
3M=pre-stimulation and 3-months only, 
*No FAS questionnaire data available 
 
  
Chapter 3. Mood 
60 
Patients 003 and 021 were severely disabled, unresponsive and could not 
complete the questionnaires, therefore they were removed from data analysis. 
Patients 007 and 010 were lost to follow up after 3 months of VNS treatment but 
were included in data analysis. FAS scores were not available for patients 001 
and 007 as this questionnaire was added to the study after these patients were 
implanted with the VNS device. A full set of data was available for the remaining 
11 patients (Table 3-1).   
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Figure 3-2 Individual change in seizure frequency and questionnaire scores in individual 
patients 
Summary of individual changes in (A) seizure frequency over a 4-week period, (B) seizure 
severity, (C) depression in epilepsy, (D) anxiety, (E) fatigue, and (F) perceived stress. PS = Pre-
stimulation, 3M = 3 months, 6M = 6 months. 
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Figure 3-2 Individual change in seizure frequency and questionnaire scores in individual 
patients (cont’d) 
Summary of individual changes in (A) seizure frequency over a 4-week period, (B) seizure 
severity, (C) depression in epilepsy, (D) anxiety, (E) fatigue, and (F) perceived stress. PS = Pre-
stimulation, 3M = 3 months, 6M = 6 months. 
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Figure 3-3 Change in seizure frequency and questionnaire scores in individual patients 
Summary of differences for (A) seizure frequency over a 4-week period, (B) seizure severity, (C) 
depression in epilepsy, (D) anxiety, (E) fatigue, and (F) perceived stress. PS = Pre-stimulation, 
3M = 3 months, 6M = 6 months. 
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Figure 3-3 Change in seizure frequency and questionnaire scores in individual patients 
(cont’d) 
Summary of differences for (A) seizure frequency over a 4-week period, (B) seizure severity, (C) 
depression in epilepsy, (D) anxiety, (E) fatigue, and (F) perceived stress. PS = Pre-stimulation, 
3M = 3 months, 6M = 6 months. 
 
Table 3-2 Statistical analysis of questionnaires  
One-way 
ANOVA 
p value 
(n=6) 
3M – PS (n=13) 6M – PS (n=11) 
Mean 
diff. 
SD of 
diff. 
T test 
p value 
Mean 
diff. 
SD of 
diff. 
T test 
p value 
LSSS 0.1929 -6.846 15.19 0.1301 -3.636 15.75 0.4615 
NDDI-E 0.9114 -0.231 2.976 0.7846 -0.273 3.58 0.8057 
GAD-7 0.537 -1.077 3.378 0.2727 -0.727 3.927 0.5527 
FAS* 0.5045 -2.182 5.741 0.2362 -2.8 9.818 0.3906 
PSS 0.1653 -3.000 6.258 0.1095 -4.545 7.751 0.0804 
* for FAS, n=11 for 3M - PS, and n = 10 for 6M - PS 
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 Seizure Frequency and Severity 
A total of 5/13 patients at 3 months and only 1/11 patient at 6 months achieved a 
>50% reduction in seizure frequency (Figure 3-2A and Figure 3-3A). An average 
change in seizure frequency of -6.85 ± 69.83 seizures was observed at 3 months 
and +24.08 ± 48.16 seizures at 6 months (Table 3-2), equating to a relative 
seizure frequency of +40.52% ± 261.86% observed at 3 months and +110.41% 
± 206.05% at 6 months compared to pre-stimulation. No significant change in 
seizure frequency was detected by one-way ANOVA and T test analysis following 
VNS implantation (Table 3-2). 
A decrease in seizure severity was observed in 9/13 patients at 3-months and 
5/11 patients at 6-months (Figure 3-2B and Figure 3-3B). Seizure severity 
scores reduced on average by -6.846 ± 15.19 at 3 months and -3.636 ± 15.75 at 
6 months compared to pre-stimulation (Table 3-2). No significant changes in 
LSSS scores were detected by one-way ANOVA and T test analysis following 
VNS implantation (Table 3-2), and changes in seizure severity were independent 
of changes in seizure frequency. 
 Depression in Epilepsy 
A decrease in depression was observed in 5/13 patients at 3 months and 5/11 
patients at 6 months (Figure 3-2C and Figure 3-3C). NDDI-E score reduced on 
average by -0.2308 ± 2.976 at 3 months and -0.2727 ± 3.58 at 6 months 
compared to pre-stimulation (Table 3-2). No significant changes in NDDI-E 
scores were detected by one-way ANOVA and T test analysis following VNS 
implantation (Table 3-2). Changes in NDDI-E scores were independent of age, 
gender, and changes in seizure frequency and severity. No trends were found 
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when comparing changes in NDDI-E scores to changes in PSS, GAD-7, or FAS 
scores. 
 Generalised Anxiety 
A decrease in generalised anxiety was observed in 6/13 patients at 3 months and 
5/11 patients at 6 months (Figure 3-2D and Figure 3-3D). GAD-7 scores reduced 
on average by -1.077 ± 3.378 at 3 months and -0.7273 ± 3.927 at 6 months 
compared to pre-stimulation (Table 3-2). No significant changes in GAD-7 scores 
were detected by one-way ANOVA and T test analysis following VNS 
implantation (Table 3-2). Changes in GAD-7 scores were independent of age, 
gender, and changes in seizure frequency and severity. Furthermore, no trends 
were found when comparing changes in GAD-7 scores to changes in NDDI-E, 
PSS, or FAS scores. 
 Fatigue 
A decrease in fatigue was observed in 8/11 patients at 3 months and 5/10 patients 
at 6 months (Figure 3-2E and Figure 3-3E). FAS scores reduced on average by 
-2.182 ± 5.741 at 3 months and -2.8 ± 9.818 at 6 months compared to pre-
stimulation (Table 3-2). No significant changes in FAS scores were detected by 
one-way ANOVA and T test analysis following VNS implantation (Table 3-2). No 
trends were found when comparing changes in FAS scores to changes in 
NDDI-E, PSS, or GAD-7 scores. 
 Perceived Stress 
A decrease in perceived stress was observed in 8/13 patients at 3 months and 
7/11 patients at 6 months (Figure 3-2F and Figure 3-3F). PSS scores reduced 
on average by -3.00 ± 6.258 at 3 months and -4.545 ± 7.751 at 6 months 
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compared to pre-stimulation (Table 3-2). A trend in decreasing PSS scores was 
observed and was approaching statistical significance at 6 months (T-test p=0.08, 
one-way ANOVA p=0.1653, Table 3-2). Changes in PSS scores were 
independent of age, gender, and changes in seizure frequency and severity. 
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 Discussion 
 Seizure Frequency and Severity 
VNS did not reduce seizure frequency in the majority of patients at 3- and 6-
months post-VNS implantation (Figure 3-2A, Figure 3-3A) with only 1 patient 
achieving >50% seizure reduction by 6 months (Figure 3-2A, Figure 3-3A). 
Cukiert’s study reports 31-39% of VNS patients achieving a >50% reduction in 
seizure frequency 2 years post-VNS implantation (Cukiert, 2015). Since 
stimulation intensities were still being adjusted by the end of the study, the 
individual optimal VNS stimulation paradigm is yet to be achieved in the majority 
of patients in the current study. 
A small mean decrease in seizure severity was present (Figure 3-2B), and 
approximately half of all patients in the study achieved a reduction in seizure 
severity (Figure 3-3B). Our findings were in line with other studies which have 
used the seizure severity questionnaire (SSQ) (Fisher et al., 2015) and the 
National Hospital Seizure Severity Scale (NHS3) (Boon et al., 2015; Fisher et al., 
2015) to monitor changes in seizure severity. In both studies, they detected a 
small but significant reduction in seizure severity scores at 3-, 6-, and 12-months 
following VNS implantation. Furthermore, Shahwan et al. assessed seizure 
severity through monitoring the frequency and duration of seizures, need for 
emergency medications to stop seizures, and intensity of seizures and speed of 
recovery. They also report a small reduction in seizure severity following 
>18 months VNS implantation in children (Shahwan et al., 2009).  
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 Mood 
We report a trend in decreasing perceived stress scores and minor reduction in 
depression scores over time. We did not find changes in anxiety or fatigue 
following VNS treatment. 
Depression 
We observed a minor decrease in NDDI-E scores for only 3 patients up to 6 
months after VNS implantation. However, this was not found to be statistically 
significant. This was similar to the NDDI-E scores observed in a randomised long-
term effectiveness trial for VNS patients which found a mean reduction in NDDI-
E scores after 6 months (-1.1 ± 3.3) and 12 months (-1.0 ± 2.2) of VNS treatment 
(when compared to best medical practice control group, at 6 months p=0.02, at 
12 months p=0.28) (Ryvlin et al., 2014). Similar reductions in depression were 
found 3-months post-VNS implantation with the Beck Depression Inventory (BDI, 
mean difference vs baseline: -2.6, p=0.045) and Hamilton Rating Scale for 
Depression (Ham-D, mean difference vs baseline: -4.1, p=0.017) (Harden et al., 
2000). 
Anxiety 
No change in anxiety was observed up to 6 months following VNS implantation. 
This finding was similar to the pilot study by Harden et al. where anxiety 
(assessed by the Hamilton Rating Scale for Anxiety (Ham-A)) did not show any 
significant change 3-months post-VNS implantation (mean difference vs pre-
stimulation: -1.0, p=0.277) (Harden et al., 2000). Despite this, George et al. 
suggested deploying VNS in patients with anxiety disorders (obsessive 
compulsive disorder, post-traumatic stress disorder, and panic disorder) following 
4/9 patients having received sustained improvements in anxiety scores (mean 
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change in HAM-A: -8.1, p>0.05) 4 years post-VNS implantation compared to pre-
stimulation (George et al., 2008). 
Fatigue 
Fatigue did not significantly change in the current study. Although one study 
assessing safety and efficacy of VNS in treating fibromyalgia reported increased 
fatigue in 3 of 14 patients (Lange et al., 2011), a Cochrane review on VNS in 
partial seizures concluded that fatigue was not significantly associated with VNS 
treatment (Panebianco et al., 2015). In the current study, 4/10 patients had 
increased fatigue according to the FAS but did not report fatigue as a side effect 
or adverse event as a result of VNS. 
Perceived stress 
We identified a trend in reducing PSS score 6 months after VNS implantation. 
Subsequent sample size calculations predict an additional 9 patients would be 
sufficient to detect this change after 6 months of VNS treatment. Although there 
are currently no studies reporting changes in perceived stress following VNS in 
adults, one study investigated changes in parenting stress in parents of children 
with refractory epilepsy before and after VNS implantation reports reduced 
parent-child interaction-associated stress following VNS implantation in children 
(Li et al., 2017). This study used parental stress index (PSI) to assess various 
aspects of stress associated with parent-child interaction with separate domains 
assessing theses stresses in parents and children. Scores from the children 
domain of the questionnaire show no significant changes in stress 12 months 
following VNS (n=30) (Li et al., 2017). The differences in changes in stress 
observed between the current study and Li et al. is possibly due to differences in 
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tools used. Whilst the PSS scale is targeted for general perceived stress in adult, 
the PSI focuses on stress arising from interaction between parent and child.  
In conclusion, while efficacious VNS settings have not yet been achieved, we 
report a trend in reducing perceived stress independent of age, gender, and 
changes in seizure, depression, anxiety and fatigue at 6 months following VNS 
treatment. 
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Chapter 4. Heart Rate Variation 
 Introduction 
A dysfunctional ANS or blunted vagal tone from measures of HRV can be found 
in patients with epilepsy, mood disorders, and inflammatory gastrointestinal 
diseases from measures of HRV (Pellissier et al., 2010; Ponnusamy, Marques 
and Reuber, 2012; Sgoifo et al., 2015). VNS treatment in these patients altered 
various measures of HRV which indicated a restored balance in autonomic tone 
(Setty et al., 1998; Galli et al., 2003; Sperling et al., 2010; Bonaz et al., 2016). 
HRV has also been identified as a potential indicator to predict responsiveness 
to VNS treatment in refractory epilepsy patients (Liu et al., 2017). In this study, 
we explored other changes in HRV following VNS treatment and compared this 
to the other beneficial changes observed from questionnaires (Chapter 3), cell 
frequencies, functional capacities of cells, and cytokine expression (Chapter 5) 
 
Aim 2: To determine the effects of VNS on HRV 
Hypothesis: VNS will enhance HRV and this will correlate with the beneficial 
effects of VNS. 
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 General Methodology 
5-minute ECG recordings were obtained at each patient visit and a 3-min artefact-
free recordings were used to calculate HRV parameters in Kubios. Additionally, 
non-linear measures of autonomic tone: CSI and CVI were calculated according 
to the equations in Section 2.2.5. 
One-way ANOVAs with repeated measures and Tukey correction were used to 
analyse full sets of data excluding patients 007 and 010 which data for only pre-
stimulation (PS) and 3 months were available. Separate pair-wise T test 
comparisons with Bonferroni correction was used to test for differences in 
measures of HRV between timepoints for all samples. Changes in measures of 
HRV were compared to differences in age and gender. 
Values and differences between timepoints for measures of HRV in individual 
patients were plotted against questionnaire scores (Chapter 3), cell frequencies, 
measures of cell function, and expression of cytokines (Chapter 5). Due to the 
small sample size, resulting graphs were visually inspected for trends between 
variables to identify potential measures of HRV as indicators of other outcomes 
in the study. 
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 Results 
 Recruitment 
 
Figure 4-1 Summary of recruitment for HRV analysis 
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Table 4-1 Summary of recruited patients for HRV analysis 
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001 39 F ✔ 105 1.25 20 250 30 5 
007 42 F 3M 106 1.00 15 250 30 5 
010 46 F 3M 106 1.00 25 250 30 5 
011 22 M 3M 106 1.13 20 250 30 1.8 
013 34 M 3M 105 1.25 20 250 30 3 
014 46 F ✔ 105 1.00 20 250 30 1.8 
015 23 M 6M 105 1.75 25 250 30 1.8 
016 25 M ✔ 105 0.75 30 250 30 3 
020 21 M ✔ 105 1.75 25 250 30 1.8 
022 42 F ✔ 105 1.50 20 250 30 3 
023 53 F ✔ 105 1.25 20 250 30 1.8 
024 22 M ✔ 105 1.50 20 250 30 1.8 
✔=full set of data available, 
3M=pre-stimulation and 3-months only, 
6M=pre-stimulation and 6-months only 
 
A total of 15 patients were recruited into the study. Patients 003 and 021 were 
removed from the study due to severe learning disabilities and were not able to 
remain still during ECG recordings. Patient 004 was removed from the dataset 
due to an underlying heart condition. Patients 007 and 010 were lost to follow up 
after 3 months of VNS treatment but were included in data analysis. Data from 
patient 015 at 3 months and patients 011 and 013 at 6 months did not contain 
3-minute artefact-free samples and were not included in data analysis. 
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Figure 4-2 Cardiac effects in individuals following VNS in individual patients 
Summary of individual changes in (A) heart rate, (B) standard deviation in heart rate, (C) HRV 
triangular index, (D) LF relative power, (E) HF relative power, (F) LF/HF ratio, (G) cardiac 
sympathetic index (CSI), and (H) cardiac vagal index (CVI). PS = Pre-stimulation, 3M = 3 months, 
6M = 6 months. ** = p<0.01. 
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Figure 4-2 Cardiac effects in individuals following VNS in individual patients (cont’d) 
Summary of individual changes in (A) heart rate, (B) standard deviation in heart rate, (C) HRV 
triangular index, (D) LF relative power, (E) HF relative power, (F) LF/HF ratio, (G) cardiac 
sympathetic index (CSI), and (H) cardiac vagal index (CVI). PS = Pre-stimulation, 3M = 3 months, 
6M = 6 months. ** = p<0.01. 
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Figure 4-3 Changes in measures of HRV in individual patients 
Summary of differences for (A) heart rate, (B) standard deviation in heart rate, (C) HRV triangular 
index, (D) LF relative power, (E) HF relative power, (F) LF/HF ratio, (G) cardiac sympathetic 
index(CSI), and (H) cardiac vagal index (CVI). PS = Pre-stimulation, 3M = 3 months, 6M = 6 
months. 
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Figure 4-3 Changes in measures of HRV in individual patients (cont’d) 
Summary of differences for (A) heart rate, (B) standard deviation in heart rate, (C) HRV triangular 
index, (D) LF relative power, (E) HF relative power, (F) LF/HF ratio, (G) cardiac sympathetic 
index(CSI), and (H) cardiac vagal index (CVI). PS = Pre-stimulation, 3M = 3 months, 6M = 6 
months. 
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Table 4-2 HRV parameter analysis 
 
One-way 
ANOVA 
p value 
(n=7) 
3M – PS (n=11) 6M – PS (n=8) 
Mean 
diff. 
SD of 
diff. 
T test 
p 
value 
Mean 
diff. 
SD of 
diff. 
T test 
p 
value 
Mean HR 
(bpm) 
0.211 +1.162 10.17 0.7127 +3.885 6.628 0.1413 
STD HR (bpm) 0.4489 +0.5203 1.31 0.2171 +0.1164 1.496 0.8321 
HRV 
Triangular 
Index 
0.3912 -1.022 3.759 0.3882 -0.0931 3.115 0.935 
LF Relative 
Power (%) 
0.235 +6.625 21.85 0.3383 -8.021 10.8 0.0738 
HF Relative 
Power (%) 
0.3939 -0.4536 12.45 0.9062 -6.381 5.149 0.0099 
LF/HF Ratio 0.6487 +0.2188 1.775 0.6911 +0.1161 0.7713 0.6832 
CSI 0.3974 -0.0022 0.1593 0.9637 -0.0580 0.1054 0.1638 
CVI 0.9474 +0.0294 0.2456 0.6996 -0.1459 0.56 0.4852 
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One-way ANOVA with repeated measures and Tukey corrections did not identify 
any significant changes in measures of HRV over time (Table 4-2). 
Mean heart rate (Table 4-2) increased by 1.162 ± 10.17 beats per minute (bpm) 
at 3 months and 3.885 ± 6.628 bpm at 6 months compared to PS. Patient 011 
had a high resting heart rate (HR) 122 bpm at PS and reduced to 95 bpm at 
3 months. Although this large decrease in HR, this was likely attributed to 
increased exercise and weight loss. We did not find cases of bradycardia in the 
current study. 
6/8 patients displayed a reduced LF relative power (ms2) (Figure 4-2D and 
Figure 4-3D) and the reduction in mean LF relative power by 6 months was 
approaching significance (-8.021±10.8 ms2, T-test p=0.0738, Table 4-2). 
6/8 patients also displayed a reduced HF relative power (ms2) (Figure 4-2E and 
Figure 4-3E)and the reduction in mean HF relative power by 6 months was 
statistically significant ( -6.381±5.149 ms2, T test p=0.0099, Table 4-2). No other 
measures of HRV changed significantly over time following VNS implantation 
according to one-way ANOVA and T test analysis (Table 4-2). 
Changes in HRV were independent of age and gender (data not shown). Data 
from individual patients for different measures of HRV were compared to 
questionnaire results from Chapter 3 and cell frequency, cell function, and 
cytokine expression results from Chapter 5 but no trends were observed (data 
not shown). 
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 Discussion 
VNS did not induce bradycardia in the current study. On the contrary, we report 
an increased mean heart rate (HR) at 3 and 6-month post-VNS implantation but 
was not significantly different to HR at pre-stimulation. No significant changes in 
HR at 3 and 12 months were reported in a large clinical trial (n=195) observing 
the long term effects of VNS (Handforth et al., 1998; DeGiorgio et al., 2000). 
We report a significant reduction in mean HF relative power 6 months following 
VNS implantation and the sample size was sufficiently powered to detect this 
(Appendix Table 3). LF is traditionally considered a measure of vagal tone while 
HF is more complex and assumed to reflect mainly sympathetic tone (Task Force 
of the European Society of Cardiology the North American Society of Pacing 
Electrophysiology, 1996). The significance of changes in HRV and how VNS is 
affecting balance between the sympathetic and vagal tone is unclear however. 
While some have reported an increased HF power (ms2) and standard deviation 
of RR intervals (SDNN) following VNS (Libbus et al., 2015), others report reduced 
HF power (ms2) (Liu et al., 2017), LF power (ms2) and LF/HF ratio (Schomer et 
al., 2014), or no changes in HRV (Garamendi et al., 2017) following VNS 
implantation. Additionally, the current study uses 5-min recordings while other 
studies have used 24 hour ambulatory ECGs to remove circadian influence on 
HRV (Schomer et al., 2014; Garamendi et al., 2017; Liu et al., 2017). Billman 
reviewed the interpretation of LF/HF ratio and summarised data on LF/HF ratio 
to sympathetic and parasympathetic nerve activity. Due to the non-linear 
relationship between these variables, Billman concluded that LF/HF ratio does 
not accurately quantify sympathetic and parasympathetic nerve activity (Billman, 
2013). 
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No trends were observed when comparing HRV data to questionnaire scores, 
cell frequency, measures of cell function, and cytokine expression from individual 
patients (data not shown). This could be due to a number of limitations including: 
heterogeneity in patient population, maximum tolerated stimulation intensity not 
yet achieved, inadequate sample size, influence of the circadian rhythm on HRV 
and medications being taken. 
In summary, although we identify a significant increase in HF power following 
6 months of VNS treatment, we could not identify other changes which may be 
associated with changes in HRV. 
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Chapter 5. The Immune System 
 Introduction 
Inflammation is the response to damage or infections to the body and is often the 
first step in the process of clearing and repairing any damaged tissues. However, 
when this process is not controlled, excessive or chronic inflammation may 
damage surrounding healthy tissue. Most methods of controlling inflammation in 
autoimmune diseases have a pharmacological approach which may have 
unwanted adverse effects or interactions with other drugs. Vagal nerve activity 
modulates the inflammatory response and electrical stimulation of this nerve 
dampens the inflammatory response. VNS could potentially treat inflammatory 
conditions such as RA, stroke, and inflammatory GI diseases without adverse 
effects. However, its underlying mechanisms are unclear and warrant deeper 
investigation. 
Tregs are potent modulators of inflammation. Although treatment with VNS in rats 
increases Treg frequency (Morishita et al., 2015; Jeremias et al., 2016), changes 
in Tregs following VNS treatment have not been investigated in humans and may 
be key to the anti-inflammatory response seen in treatment with VNS. In this 
study, flow cytometry was performed to investigate quantitative changes in Tregs 
and other putative immune cells. 
VNS could potentially alter the immune system in other ways such as the 
functional ability of cells in response to an inflammatory stimulus. Cell division is 
a surrogate marker of cell function (Roederer, 2011); the higher number of 
divisions a cell undergoes, the higher its functional capacity in response to a 
stimulus which can be quantified as division and proliferation indices. While the 
division index is the average number of divisions a cell undergoes within a sample 
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and is an overall measure of functional capacity for the sample. The proliferation 
index is the average number of divisions a cell undergoes excluding undivided 
cells and is a measure of the function of responding cells within a sample. In this 
study, flow cytometry was used to assess these functional changes in Tregs and 
other putative immune cells against in vitro methods of stimulation to mimic 
antigen presentation (activation of CD3 receptors) and activation of TLRs (via 
enterotoxin). 
Some studies have investigated differences in cytokine expression following VNS 
(Corcoran et al., 2005; Veerle De Herdt et al., 2009; Majoie et al., 2011; Aalbers 
et al., 2012; Koopman et al., 2016), however to our knowledge, no studies have 
reported the use of cytokine arrays to observe these changes. In this study, we 
use a semi-quantitative membrane-based array to observe relative changes in 
inflammatory cytokines to assess identify any changes associated with VNS 
treatment and may indicate an enhanced anti-inflammatory or a dampened 
“inflammatory tone”. Changes in basal levels of inflammatory and anti-
inflammatory cytokines. 
 
Aim 3: To determine changes in anti-inflammatory cell frequency and 
function and in pro and anti-inflammatory cytokines after VNS 
Hypothesis: VNS will alter cell frequencies and expression of cytokines in blood 
to promote immune tolerance. Furthermore, VNS will enhance the functional 
capacity of Tregs to promote immune tolerance.  
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 General Methodology 
A total of 15 patients with refractory epilepsy recruited in the study were asked to 
provide a blood sample at each visit before and at 3- and 6-months after VNS 
implantation. Whole blood was collected from the cubital vein into vacutainers 
containing heparin. 
PBMCs were isolated by a ficoll-density gradient method according to the 
manufacturer’s protocol. Briefly, whole blood was diluted with sterile PBS and 
layered gently on top of LSM. Samples were centrifuged at 400 x g for 40 minutes 
with soft start and no brake to isolate plasma and PBMCs. 
Isolated PBMCs were divided to assess frequency of immune cell populations on 
the day of blood sampling and to assess functional changes before and 3- and 6-
months after VNS. Antibodies against cell surface markers: CD4, CD8a, CD14, 
CD19, CD25, and intracellular marker foxp3 were used to observe changes in 
monocyte, B cell, CD8 T cells, CD4 T cells, CD25+ cells, and CD4+ CD25+ foxp3+ 
Tregs via flow cytometry and analysed in FlowJo. In the functional assay, PBMCs 
were stained with a proliferation dye and incubated for 96 hours under 3 
conditions: control (unstimulated), anti-CD3 antibody-coated wells to mimic 
activation of T cells via APC pathways, and SEB to mimic activation of 
T cells via enterotoxin pathways in response to bacteria. Following incubation, 
population frequencies were assessed by flow cytometry, and the division and 
proliferation indices of each population were calculated using the FlowJo 
Proliferation platform. 
Raybiotech cytokine arrays were used to investigate changes in the levels of 80 
inflammatory cytokines from plasma according to manufacturer protocol. Briefly, 
cytokine array membranes were incubated with plasma samples, secondary 
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antibody cocktail, then HRP-streptavidin. The relative expression of cytokines 
was measured via chemiluminescence imaging and given as a percentage 
relative to the average of positive controls. This was analysed using paired T test 
with Bonferroni correction. 
  
Chapter 5. The Immune System 
90 
 Results 
 Recruitment 
A total of 5 healthy volunteers were recruited from the University of Sheffield and 
blood samples were collected for the optimisation of flow cytometry and cytokine 
array assays. A summary of patient recruitment for analysing the anti-
inflammatory effects of VNS can be found below (Figure 5-1). 
 
Figure 5-1 Summary of recruitment for analysing anti-inflammatory effects of VNS 
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Table 5-1 Summary of patients for analysing anti-inflammatory effects of VNS 
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011 22 M ✔ ✔ ✖ 106 1.13 20 250 30 1.8 
014 46 F ✔ ✔ ✔ 105 1.00 20 250 30 1.8 
016 25 M ✔ ✔ ✔ 105 0.75 30 250 30 3 
020 21 M ✔ ✔ ✔ 105 1.75 25 250 30 1.8 
022 42 F ✔ ✔ ✔ 105 1.50 20 250 30 3 
✔=full set of data available, ✖=data not available 
 
Blood samples from 5 of the 15 recruited patients were obtained prior to VNS 
implantation PS and at 3- and 6-months post- VNS implantation. A full list of 
medications taken for patients 011, 014, 016, and 022 are available in Appendix 
Section 8.3. The list of medications taken for patient 020 was not available. 
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 Optimisation of flow cytometry assay 
The ThermoFisher Fluorescence SpectraViewer was used to identify fluorophore 
and fluorescent dyes compatible with the available 4-laser flow cytometer (LSRII) 
and its configuration at the University of Sheffield (Appendix Figure 2). 
Commercially available antibodies conjugated to compatible fluorophores and 
fluorescent dyes were selected, and a panel consisting of 6 fluorescent antibodies 
with 6 fluorescent isotype controls, a UV cell viability dye and a fluorescent cell 
proliferation marker were used in the study (Table 5-2). 
Table 5-2 Flow cytometry antibody and dye panel with corresponding controls  
Antibody/Dye Control 
Mouse anti-human CD4:FITC Mouse IgG2b K Isotype Control FITC 
Mouse anti-human CD25:PE Mouse IgG1 K Isotype Control PE 
Mouse anti-human CD8a APC-eFluor780 Mouse IgG1 K Isotype Control APC-eFluor780 
Mouse anti-human CD14:PerCP-Cy5.5 Mouse IgG1 K Isotype Control PerCP-Cy5.5 
Mouse anti-human CD19:PE-Cy7 Mouse IgG1 K Isotype Control PE-Cy7 
Rat anti-human Foxp3:APC Rat IgG2a K Isotype Control APC 
UV cell viability dye Unstained PBMCs 
Cell Proliferation Dye eFluor® 450 Unstained PBMCs 
 
Blood samples collected from 5 adult healthy volunteers (2 male, 3 female) were 
used to isolate PBMCs using the manufacturer’s protocol for the LSM (Lonza). 
PBMCs. Isolated PBMCs were incubated and stained according to the methods 
outlined in (Section 2.2.7).  
Unstained PBMCs were used to calibrate voltages for forward and side scatter 
detection plates (used to detect size and granularity of cells) which also served 
as a negative control. PBMCs stained only with cell viability dye, PBMCs stained 
only with cell proliferation dye, and flow cytometry beads incubated with individual 
fluorescent antibodies (positive beads – affinity to mouse or rat antigen, negative 
beads – no affinity to mouse or rat antigens) were used to calibrate the voltages 
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of each coloured detector for the first run. PBMCs were incubated with fluorescent 
isotype antibodies as another negative control to ensure specific binding of 
fluorescent antibodies against CD4, CD25, foxp3, CD8a, CD14 and CD19. 
Isotype controls and unstained cells were used to determine the positive or 
negative expression of a receptor or dye. Optimised voltages were fixed in 
subsequent runs and all controls mentioned above were used at each run to 
ensure consistency and sensitivity between runs.  
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 Cell Population Frequency 
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Figure 5-2 Cell frequency on day of blood sampling in individual patients 
Frequency of cell types in the monocyte gate: (A) Monocyte; lymphocyte gate: (B) B cell, (C) 
CD8a+ cells, (D) CD4+ cells, (E) CD25+ cells, (F) CD4+ CD25+ cells, and (G) Tregs. (H) 
Frequency of Tregs in CD4+ cells. (I) Frequency of Tregs in CD4+ CD25+ cells. * = p<0.05. 
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Figure 5-2 Cell frequency on day of blood sampling in individual patients (cont’d) 
Frequency of cell types in the monocyte gate: (A) Monocyte; lymphocyte gate: (B) B cell, (C) 
CD8a+ cells, (D) CD4+ cells, (E) CD25+ cells, (F) CD4+ CD25+ cells, and (G) Tregs. (H) 
Frequency of Tregs in CD4+ cells. (I) Frequency of Tregs in CD4+ CD25+ cells. * = p<0.05.  
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Figure 5-3 Difference in cell frequency on day of blood sampling in individual patients 
Differences in cell population frequencies for (A) Monocyte, (B) B cell, (C) CD8a+ cells, (D) CD4+ 
cells, (E) CD25+ cells, (F) CD4+ CD25+ cells, and (G) Tregs. Differences in frequency of Tregs 
expressed as a % of (H) CD4+ cells and (I) CD4+ CD25+ cells.   
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Figure 5-3 Difference in cell frequency on day of blood sampling in individual patients 
(cont’d) 
Differences in cell population frequencies for (A) Monocyte, (B) B cell, (C) CD8a+ cells, (D) CD4+ 
cells, (E) CD25+ cells, (F) CD4+ CD25+ cells, and (G)Tregs. Differences in frequency of Tregs 
expressed as a % of (H) CD4+ cells and (I) CD4+ CD25+ cells.   
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Table 5-3 Analysis of cell frequency on day of blood sampling 
Cell 
One-way 
ANOVA 
p value 
(n=5) 
3M – PS (n=5) 6M – PS (n=5) 
Mean 
diff. 
(%) 
SD of 
diff. 
(%) 
T test 
p value 
Mean 
diff. 
(%) 
SD of 
diff. 
(%) 
T test 
p value 
Monocyte 0.1958 -0.242 2.59 0.8447 -2.13 1.725 0.0508 
B cell 0.896 -0.294 3.872 0.8734 -0.41 3.053 0.7789 
CD8+ 0.6717 -1.272 1.873 0.2035 -0.852 4.369 0.6853 
CD4+ 0.6297 +0.554 1.026 0.2936 -0.634 4.299 0.7581 
CD25+ 0.2753 +1.732 2.907 0.2536 +2.022 1.354 0.0289 
CD4+CD25+ 0.1966 +0.366 1.864 0.6832 +1.8 1.085 0.0207 
Treg 0.2768 +0.326 0.5908 0.2848 +0.45 0.755 0.2535 
Treg/CD4+ 0.21 +0.69 1.17 0.2577 +0.92 1.159 0.1506 
Treg/CD4+CD25+ 0.3129 +4.28 11.42 0.4492 -3.288 8.322 0.4269 
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Comparing differences in cell population frequencies in individuals revealed a 
reduction in monocytes for 5/5 patients (Figure 5-2A and Figure 5-3A) and 
increase in CD25+ cells for 4/5 patients (Figure 5-2E and Figure 5-3E) and CD4+ 
CD25+ cells for 4/5 patients (Figure 5-2F and Figure 5-3F) at 6 months. There 
was an increased expression of Tregs in CD4+ CD25+ cells for 4/5 patients at 
3 months (Figure 5-2I and Figure 5-3I), and CD4+ cells for 5/5 patients at 
6 months (Figure 5-2H and Figure 5-3H). No other trends in cell frequencies 
were found. 
One-way ANOVA analysis (Table 5-3) did not detect significant change over time 
in any of the tested cell populations. However, paired T test analysis (Table 5-3) 
revealed a significant increase of +2.022±1.354% in CD25+ (p=0.0289) and 
+1.8±1.085% in CD4+ CD25+ cells (p=0.0207) from the lymphocyte gate at 6 
months post-VNS implantation compared to pre-stimulation in 5/5 patients. A 
reduction of -2.13±1.725% in monocyte population from the monocyte gate was 
detected by 6-months post-VNS implantation in 5/5 patients and was 
approaching statistical significance (p=0.0508).  
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 Functional Assay 
 Frequency 
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Figure 5-4 Cell frequencies following functional assay 
Mean cell population frequencies for (A) Monocyte, (B) B cell, (C) CD8+, (D) CD4+, (E) CD25+, 
(F) CD4+ CD25+ and (G-I) Tregs. Treg expression also displayed as a percentage of (H) CD4+ 
and (I) CD4+ CD25+ cells. PS = pre-stimulation, 3M = 3 months -post VNS implantation, 6M = 6-
months post VNS implantation. Error bars = standard deviation. Paired T test comparison with 
Tukey correction p value: *p<0.05 between timepoints within the aCD3 (red) or SEB (green) 
groups. 
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Figure 5-4 Cell frequencies following functional assay (cont’d) 
Mean cell population frequencies for (A) Monocyte, (B) B cell, (C) CD8+, (D) CD4+, (E) CD25+, 
(F) CD4+ CD25+ and (G-I) Tregs. Treg expression also displayed as a percentage of (H) CD4+ 
and (I) CD4+ CD25+ cells. PS = pre-stimulation, 3M = 3 months -post VNS implantation, 6M = 6-
months post VNS implantation. Error bars = standard deviation. Paired T test comparison with 
Tukey correction p value: *p<0.05 between timepoints within the aCD3 (red) or SEB (green) 
groups.  
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Figure 5-5 Difference in cell frequency following functional assay in individual patients 
Differences in cell frequency for (A) Monocyte, (B) B cell, (C) CD8+, (D) CD4+, (E) CD25+, (F) 
CD4+ CD25+ and (G-I) Tregs in individuals between 3 months post-VNS implantation compared 
to pre-stimulation (3M-PS) and 6-months post VNS implantation compared to pre-stimulation (6M-
PS). Treg expression also displayed as a percentage of (H) CD4+ and (I) CD4+ CD25+ cells. 
Samples for patient 011 at 6M in response to SEB stimulation became infected during incubation 
and were not included in data analysis.  
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Figure 5-5 Difference in cell frequency following functional assay in individual patients 
(cont’d) 
Differences in cell frequency for (A) Monocyte, (B) B cell, (C) CD8+, (D) CD4+, (E) CD25+, (F) 
CD4+ CD25+ and (G-I) Tregs in individuals between 3 months post-VNS implantation compared 
to pre-stimulation (3M-PS) and 6-months post VNS implantation compared to pre-stimulation (6M-
PS). Treg expression also displayed as a percentage of (H) CD4+ and (I) CD4+ CD25+ cells. 
Samples for patient 011 at 6M in response to SEB stimulation became infected during incubation 
and were not included in data analysis.  
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Table 5-4 Two-way ANOVA of cell frequency following functional assay 
 
Two-way ANOVA p values 
Time Condition 
Time x 
Condition 
Monocyte 0.7265 0.0002 0.593 
B cell 0.6395 0.0003 0.3636 
CD8+ 0.6873 0.1372 0.5009 
CD4+ 0.4842 0.0037 0.5109 
CD25+ 0.1768 0.0003 0.2276 
CD4+CD25+ 0.2361 <0.0001 0.2645 
Treg 0.2158 0.0002 0.2643 
Treg/CD4+ 0.1181 0.001 0.1465 
Treg/CD4+ CD25+ 0.1122 0.0043 0.5385 
 
Table 5-5 Paired T test for cell frequency following functional assay 
 
  
Cell Condition Comparison 
Mean 
Diff. (%) 
SD of 
Diff. (%) 
Paired T test 
P Value 
M
o
n
o
c
y
te
 
Control 
3M-PS -6.848 5.932 0.061 
6M-PS -0.098 2.867 0.943 
aCD3 
3M-PS -6.224 23.586 0.587 
6M-PS -17.516 29.829 0.259 
SEB 
3M-PS -9.126 15.666 0.263 
6M-PS -5.903 32.273 0.739 
B
 C
e
ll
 
Control 
3M-PS +2.520 3.207 0.154 
6M-PS +2.378 4.472 0.300 
aCD3 
3M-PS +2.328 1.822 0.046 
6M-PS +0.674 4.416 0.750 
SEB 
3M-PS -0.264 0.920 0.556 
6M-PS -0.505 0.869 0.329 
C
D
8
 T
 C
e
ll
 
Control 
3M-PS +0.570 3.307 0.720 
6M-PS -1.106 2.451 0.370 
aCD3 
3M-PS -2.894 5.985 0.340 
6M-PS -3.582 5.781 0.238 
SEB 
3M-PS +2.912 7.483 0.433 
6M-PS +1.488 2.801 0.366 
C
D
4
 T
 C
e
ll
 
Control 
3M-PS -3.804 2.778 0.038 
6M-PS -2.078 3.878 0.297 
aCD3 
3M-PS -2.656 7.226 0.457 
6M-PS +0.090 8.717 0.983 
SEB 
3M-PS +1.176 6.577 0.710 
6M-PS +3.153 7.857 0.481 
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Table 5-4 Paired T test for cell frequency following functional assay (cont’d) 
 
Cell Condition Comparison 
Mean 
Diff. (%) 
SD of 
Diff. (%) 
Paired T test 
P Value 
C
D
2
5
+
 C
e
ll
 
Control 
3M-PS -1.088 1.913 0.272 
6M-PS -0.958 1.342 0.186 
aCD3 
3M-PS -10.558 11.343 0.106 
6M-PS -4.228 10.701 0.427 
SEB 
3M-PS -11.748 7.549 0.025 
6M-PS +1.013 18.475 0.920 
C
D
4
+
 C
D
2
5
+
 C
e
ll
 
Control 
3M-PS -0.950 1.723 0.285 
6M-PS -0.694 1.190 0.262 
aCD3 
3M-PS -6.164 6.649 0.107 
6M-PS -1.640 8.663 0.694 
SEB 
3M-PS -6.430 4.776 0.040 
6M-PS +2.748 12.628 0.693 
T
re
g
 
Control 
3M-PS -0.602 0.818 0.175 
6M-PS -0.466 0.661 0.190 
aCD3 
3M-PS -9.090 6.003 0.028 
6M-PS -7.216 7.893 0.110 
SEB 
3M-PS -7.248 4.566 0.024 
6M-PS +0.440 10.934 0.941 
T
re
g
/C
D
4
+
 
Control 
3M-PS -1.002 1.592 0.232 
6M-PS -0.686 1.309 0.306 
aCD3 
3M-PS -18.858 11.173 0.020 
6M-PS -14.560 11.884 0.052 
SEB 
3M-PS -13.294 10.007 0.041 
6M-PS -0.075 15.854 0.993 
T
re
g
/C
D
4
+
 C
D
2
5
+
 
Control 
3M-PS -3.456 12.036 0.556 
6M-PS -4.498 11.977 0.448 
aCD3 
3M-PS -21.910 15.331 0.033 
6M-PS -18.794 16.300 0.061 
SEB 
3M-PS -16.534 16.772 0.092 
6M-PS -5.020 19.403 0.641 
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A trend in reduced monocyte frequency was seen in PBMCs incubated with anti-
CD3 antibody and SEB (Figure 5-4A and Figure 5-5A), and increased 
frequencies for B cells (Figure 5-4B and Figure 5-5B). Treg frequency reduced 
when incubated with anti-CD3 antibody 3 months following VNS implantation 
(Figure 5-4G and H, and Figure 5-5G and H). No other trends in cell frequency 
were found. 
Two-way ANOVA for cell population frequencies (Table 5-5) showed significant 
differences between conditions in all cell populations except CD8+ cells. No 
significant effects were seen over time and between time and conditions. 
Pair-wise comparisons (Table 5-5) revealed significant increase in B cell 
frequency (p=0.046) and reduction in Treg frequency (when calculated as % of 
lymphocytes: p=0.028, % of CD4+ cells: p=0.020, and % of CD4+ CD25+ cells 
p=0.033) in response to anti-CD3 antibody at 3 months. Significant decreases in 
were also found for CD25+ cell (p=0.025), CD4+ CD25+ cell (p=0.040), and Treg 
frequency (when calculated as % of lymphocytes: p=0.024) in response to SEB 
at 3 months. The expression of Tregs within the CD4+ and CD4+ CD25+ 
population decreased at 3 months post-VNS implantation in response to anti-CD3 
antibody.   
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Figure 5-6 Division index of cells following functional assay 
Mean division indices for (A) Monocyte, (B) B cell, (C) CD8+, (D) CD4+, (E) CD25+, (F) CD4+ 
CD25+ and (G) Tregs. PS = pre-stimulation, 3M = 3 months -post VNS implantation, 6M = 6-
months post VNS implantation. Error bars = standard deviation. Paired T test comparison with 
Tukey correction p value: *p<0.05, **p<0.001 between timepoints within the aCD3 (red) or SEB 
(green) groups. 
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Figure 5-6 Division index of cells following functional assay (cont’d) 
Mean division indices for (A) Monocyte, (B) B cell, (C) CD8+, (D) CD4+, (E) CD25+, (F) CD4+ 
CD25+ and (G) Tregs. PS = pre-stimulation, 3M = 3 months -post VNS implantation, 6M = 6-
months post VNS implantation. Error bars = standard deviation. Paired T test comparison with 
Tukey correction p value: *p<0.05, **p<0.001 between timepoints within the aCD3 (red) or SEB 
(green) groups. 
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Figure 5-7 Differences in division index of cells following functional assay in individual 
patients 
Differences in division index for (A) Monocyte, (B) B cell, (C) CD8+, (D) CD4+, (E) CD25+, (F) 
CD4+ CD25+ and (G-I) Tregs in individuals between 3 months post-VNS implantation compared 
to pre-stimulation (3M-PS) and 6-months post VNS implantation compared to pre-stimulation (6M-
PS). Treg expression also displayed as a percentage of (H) CD4+ and (I) CD4+ CD25+ cells. 
Samples for patient 011 at 6M in response to SEB stimulation became infected during incubation 
and were not included in data analysis.  
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Figure 5-7 Differences in division index of cells following functional assay in individual 
patients (cont’d) 
Differences in division index for (A) Monocyte, (B) B cell, (C) CD8+, (D) CD4+, (E) CD25+, (F) 
CD4+ CD25+ and (G-I) Tregs in individuals between 3 months post-VNS implantation compared 
to pre-stimulation (3M-PS) and 6-months post VNS implantation compared to pre-stimulation (6M-
PS). Treg expression also displayed as a percentage of (H) CD4+ and (I) CD4+ CD25+ cells. 
Samples for patient 011 at 6M in response to SEB stimulation became infected during incubation 
and were not included in data analysis.  
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Table 5-6 Two-way ANOVA of division index following functional assay 
 
Two-way ANOVA p values 
Time Condition 
Time x 
Condition 
Monocyte 0.561 0.0016 0.339 
B cell 0.345 0.0712 0.526 
CD8+ 0.809 0.0121 0.592 
CD4+ 0.759 0.0019 0.464 
CD25+ 0.054 <0.0001 0.211 
CD4+CD25+ 0.093 0.0006 0.013 
Treg 0.071 0.0018 0.001 
 
Table 5-7 Paired T test for division index following functional assay 
 
Cell Condition Comparison 
Mean 
Diff. 
SD of 
Diff. 
P Value 
M
o
n
o
c
y
te
 Control 
3M-PS -0.050 0.116 0.388 
6M-PS -0.052 0.117 0.375 
aCD3 
3M-PS -0.114 0.538 0.850 
6M-PS -0.192 0.584 0.503 
SEB 
3M-PS +0.060 0.243 0.610 
6M-PS -0.083 0.548 0.783 
B
 C
e
ll
 
Control 
3M-PS +0.016 0.286 0.906 
6M-PS -0.030 0.256 0.806 
aCD3 
3M-PS -0.290 0.354 0.141 
6M-PS -0.188 0.201 0.105 
SEB 
3M-PS -0.170 0.314 0.292 
6M-PS -0.160 0.306 0.461 
C
D
8
+
 C
e
ll
 Control 
3M-PS -0.046 0.080 0.267 
6M-PS -0.030 0.133 0.642 
aCD3 
3M-PS -0.160 0.174 0.109 
6M-PS -0.102 0.205 0.328 
SEB 
3M-PS +0.058 0.535 0.820 
6M-PS -0.083 0.617 0.806 
C
D
4
+
 C
e
ll
 Control 
3M-PS -0.040 0.075 0.298 
6M-PS -0.056 0.074 0.166 
aCD3 
3M-PS -0.094 0.256 0.457 
6M-PS -0.032 0.302 0.825 
SEB 
3M-PS -0.006 0.084 0.881 
6M-PS +0.008 0.294 0.963 
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Table 5-6 Paired T test for division index following functional assay (cont’d) 
  
Cell Condition Comparison 
Mean 
Diff. 
SD of 
Diff. 
P Value 
C
D
2
5
+
 C
e
ll
 Control 
3M-PS -0.052 0.101 0.312 
6M-PS -0.028 0.031 0.115 
aCD3 
3M-PS -0.202 0.227 0.118 
6M-PS -0.262 0.290 0.114 
SEB 
3M-PS -0.156 0.277 0.277 
6M-PS -0.188 0.235 0.208 
C
D
4
+
 C
D
2
5
+
 C
e
ll
 
Control 
3M-PS -0.040 0.101 0.428 
6M-PS -0.042 0.101 0.403 
aCD3 
3M-PS -0.152 0.345 0.381 
6M-PS -0.174 0.338 0.314 
SEB 
3M-PS -0.100 0.183 0.289 
6M-PS +0.020 0.283 0.896 
T
re
g
 
Control 
3M-PS +0.034 0.132 0.597 
6M-PS +0.030 0.073 0.411 
aCD3 
3M-PS -0.298 0.216 0.037 
6M-PS -0.396 0.105 0.001 
SEB 
3M-PS -0.050 0.123 0.416 
6M-PS +0.013 0.254 0.928 
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Comparing mean division indices over time (Figure 5-6), the control group had 
division indices of <0.1 for all cell types. PBMCS incubated with anti-CD3 
antibodies displayed a trend in reducing division indices for monocytes, B cells, 
CD4 T cells, CD25+ cells, CD4+ CD25+ cells and Tregs (Figure 5-6B, D-G). 
PBMCS incubated with SEB displayed a trend in reducing division indices for 
monocyte, B cell and CD25+ cells (Figure 5-6A, B, E). 
Comparing the changes in division index from individuals (Figure 5-7), we found 
a trend in reducing division indices for B cells, CD25+ cells, and CD4+ CD25+ 
cells in response to anti-CD3 antibodies but not in response to SEB. 
Two-way ANOVA for division indices (Table 5-7) revealed a significant difference 
between conditions over time for all cell types except B cells. Significant 
differences across time and conditions were detected for CD4+ CD25+ cells and 
Tregs.  
Pairwise comparisons (Table 5-7) revealed a significant decrease in Treg division 
in response to anti-CD3 antibodies at 3- (p=0.037) and 6-months (p=0.001) 
following VNS implantation. 
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Figure 5-8 Proliferation Index of cells following functional assay 
Mean proliferation indices for (A) Monocyte, (B) B cell, (C) CD8+, (D) CD4+, (E) CD25+, (F) CD4+ 
CD25+ and (G) Tregs. PS = pre-stimulation, 3M = 3 months -post VNS implantation, 6M = 6-
months post VNS implantation. Error bars = standard deviation. Paired T test comparison with 
Tukey correction p value: *p<0.05 between timepoints within the aCD3 (red) or SEB (green) 
groups.  
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Figure 5-8 Proliferation Index of cells following functional assay (cont’d) 
Mean proliferation indices for (A) Monocyte, (B) B cell, (C) CD8+, (D) CD4+, (E) CD25+, (F) CD4+ 
CD25+ and (G) Tregs. PS = pre-stimulation, 3M = 3 months -post VNS implantation, 6M = 6-
months post VNS implantation. Error bars = standard deviation. Paired T test comparison with 
Tukey correction p value: *p<0.05 between timepoints within the aCD3 (red) or SEB (green) 
groups.
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Figure 5-9 Differences in proliferation index of cells following functional assay in individual 
patients 
Differences in proliferation index for (A) Monocyte, (B) B cell, (C) CD8+, (D) CD4+, (E) CD25+, 
(F) CD4+ CD25+ and (G-I) Tregs in individuals between 3 months post-VNS implantation 
compared to pre-stimulation (3M-PS) and 6-months post VNS implantation compared to pre-
stimulation (6M-PS). Treg expression also displayed as a percentage of (H) CD4+ and (I) CD4+ 
CD25+ cells. Samples for patient 011 at 6M in response to SEB stimulation became infected 
during incubation and were not included in data analysis.  
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Figure 5-9 Differences in proliferation index of cells following functional assay in individual 
patients (cont’d) 
Differences in proliferation index for (A) Monocyte, (B) B cell, (C) CD8+, (D) CD4+, (E) CD25+, 
(F) CD4+ CD25+ and (G-I) Tregs in individuals between 3 months post-VNS implantation 
compared to pre-stimulation (3M-PS) and 6-months post VNS implantation compared to pre-
stimulation (6M-PS). Treg expression also displayed as a percentage of (H) CD4+ and (I) CD4+ 
CD25+ cells. Samples for patient 011 at 6M in response to SEB stimulation became infected 
during incubation and were not included in data analysis.  
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Table 5-8 Two-way ANOVA of proliferation index following functional assay 
 
Two-way ANOVA p values 
Time Condition 
Time x 
Condition 
Monocyte 0.1712 0.1167 0.855 
B cell 0.1261 0.1615 0.2123 
CD8+ 0.0016 0.0529 0.1157 
CD4+ 0.3324 0.2782 0.8344 
CD25+ 0.0398 0.0018 0.1025 
CD4+CD25+ 0.7958 0.0008 0.1206 
Treg 0.0293 0.0002 0.438 
 
Table 5-9 Paired T test for proliferation index following functional assay 
  
Cell Condition Comparison 
Mean 
Diff. 
SD of 
Diff. 
P Value 
M
o
n
o
c
y
te
 Control 
3M-PS -0.304 0.503 0.248 
6M-PS +0.026 0.633 0.931 
aCD3 
3M-PS -0.374 0.505 0.212 
6M-PS -0.212 0.315 0.207 
SEB 
3M-PS -0.338 0.318 0.076 
6M-PS -0.168 0.506 0.555 
B
 C
e
ll
 
Control 
3M-PS +0.182 0.803 0.639 
6M-PS +0.110 1.088 0.832 
aCD3 
3M-PS +0.340 0.762 0.375 
6M-PS -0.156 0.212 0.176 
SEB 
3M-PS +0.120 0.259 0.359 
6M-PS -0.457 0.228 0.074 
C
D
8
+
 C
e
ll
 Control 
3M-PS -0.358 0.365 0.093 
6M-PS -0.268 0.363 0.237 
aCD3 
3M-PS -0.110 0.323 0.489 
6M-PS -0.334 0.491 0.203 
SEB 
3M-PS -0.114 0.268 0.395 
6M-PS -0.002 0.190 0.981 
C
D
4
+
 C
e
ll
 Control 
3M-PS +0.066 1.431 0.923 
6M-PS -0.374 0.993 0.447 
aCD3 
3M-PS +0.056 0.302 0.700 
6M-PS -0.304 0.456 0.210 
SEB 
3M-PS -0.128 0.219 0.261 
6M-PS -0.165 0.452 0.518 
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Table 5-8 Paired T test for proliferation index following functional assay (cont’d) 
  
Cell Condition Comparison 
Mean 
Diff. 
SD of 
Diff. 
P Value 
C
D
2
5
+
 C
e
ll 
Control 
3M-PS +0.154 0.524 0.547 
6M-PS -0.615 0.722 0.187 
aCD3 
3M-PS -0.140 0.309 0.369 
6M-PS -0.282 0.413 0.201 
SEB 
3M-PS -0.110 0.279 0.428 
6M-PS -0.398 0.274 0.062 
C
D
4
+
 C
D
2
5
+
 C
e
ll 
Control 
3M-PS -0.052 0.500 0.828 
6M-PS +0.278 0.711 0.431 
aCD3 
3M-PS +0.054 0.485 0.815 
6M-PS -0.086 0.525 0.733 
SEB 
3M-PS -0.026 0.321 0.865 
6M-PS -0.433 0.468 0.162 
T
re
g
 
Control 
3M-PS +0.058 0.463 0.793 
6M-PS +0.003 0.897 0.996 
aCD3 
3M-PS -0.080 0.219 0.459 
6M-PS -0.376 0.269 0.035 
SEB 
3M-PS -0.456 0.612 0.171 
6M-PS -0.635 0.563 0.109 
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Mean proliferation index of samples decreased over time for CD8 T cell, CD4 
T cell, and CD25+ cells under all conditions (Figure 5-8C-E). Trends in 
decreasing proliferation index for monocyte and Treg were found in PBMCs 
incubated with anti-CD3 antibody (Figure 5-8A and G). Trends in decreasing 
proliferation indices for B cell, CD4+ CD25+ cell, and Tregs were found in PBMCs 
incubated with SEB (Figure 5-8B, F, and G).  
Comparing the changes in proliferation indices from individuals (Figure 5-9), we 
found a trend in reducing proliferation index for Treg  following in vitro stimulation 
with anti-CD3 antibody and SEB (Figure 5-9G).  
Two-way ANOVA for proliferation indices (Table 5-9) revealed a significant 
difference across time in CD8+ cells, CD25+ cells and Tregs, and between 
conditions for CD25+ cells, CD4+ CD25+ cells, and Tregs. No significant 
interaction was found between time and condition in proliferation index. 
Pairwise comparisons revealed a significant decrease in Treg proliferation index 
at 6 months post-VNS implantation when PBMCs were incubated with anti-CD3 
antibodies (p=0.035) (Table 5-9).  
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 Cytokine Array 
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Figure 5-10 Cytokine levels before and 3 months after VNS implantation in individual 
patients. 
Changes in levels of (A) BDNF, (B) FGF-7, (C) FGF-9, (D) IFN-γ, (E) IL-1α, (F) IL-1β, (G) MDC, 
(H) TGF-β1 and (I) TNF-α in individuals from cytokine arrays before VNS implantation (pre-
stimulation, PS) compared to 3 months after VNS implantation (3M). Paired T test with Bonferroni 
correction, *p<0.05, **p<0.001.  
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Table 5-10 Paired T test for cytokine array 
Cytokine 
Mean change 
relative to PS 
SD of mean 
change 
Paired T test 
p value 
IL-1β -46.78% 32% 0.0054 
IL-1α -48.32% 34% 0.0160 
FGF-9 -50.43% 34% 0.0293 
BDNF -56.01% 35% 0.0322 
FGF-7 -46.37% 33% 0.0380 
MDC -38.52% 40% 0.0491 
TNF-α -55.71% 39% 0.0504 
IFN-γ -36.26% 39% 0.0784 
TGF-β1 -55.94% 41% 0.0785 
Note: P values for paired T test was Bonferonni corrected. 
Table containing analysis for all 80 cytokines found in Appendix Table 5 
 
Paired T test comparisons of 80 cytokines identified significant decrease the 
expression of brain-derived neurotrophic factor (BDNF), fibroblast growth factor 
7 (FGF-7), fibroblast growth factor 9 (FGF-9), interleukin-1 alpha (IL-1α), 
interleukin-1beta (IL-1β), and macrophage derived chemokine (MDC) (Table 
5-10 and Figure 5-10). Reduction in the expression of TNF-α, interferon gamma 
(IFN-γ), and transforming growth factor beta 1 (TGF-β1) were approaching 
statistical significance. No other significant changes in cytokine expressions were 
observed (Appendix Table 5).  
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 Discussion 
 Cell Population Frequencies 
Flow cytometry analysis of cell population frequencies from PBMCs on the day 
of blood sampling revealed a trend in decreasing monocyte frequency following 
VNS treatment. A significant increased frequency of CD25+ cells and CD4+ 
CD25+ cells were observed 6 months following VNS treatment. Furthermore, a 
trend in increasing Treg frequency was observed. Treg frequency following VNS 
has not been previously investigated in humans, our finding is in line with the 
study by Morishita and colleagues. Here, they reported a 1% increase in Treg 
frequency following treatment with VNS in rats (Morishita et al., 2015). 
Patients in the current study had displayed higher frequency of Tregs compared 
to frequencies reported in healthy volunteers (Tregs: 0.78 ± 0.09% of 
lymphocytes) (Zahran and Elsayh, 2014). Only one study has investigated the 
frequency of Treg in epilepsy where frequency was abnormally low in children 
with epilepsy compared to healthy children (Li, Ma and Wang, 2011). One 
possible explanation for the variability in reporting Treg frequencies could be due 
to unreported differences in gating strategies during flow cytometry analysis. 
Magness and colleagues studied the reproducibility of flow cytometry data for 
murine intestinal epithelial cells and aimed to standardise its reporting for future 
studies (Magness et al., 2013). A similar approach to standardise the reporting of 
Tregs would help improve the quality of future studies.  
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 Functional Assay 
Two-way ANOVA did not reveal significant changes in cell frequencies receiving 
in vitro stimulation after VNS treatment in response to in vitro stimulation (Table 
5-4). However, T-test comparisons revealed significant reductions in Treg 
frequencies in response to aCD3 and SEB at 3 months post-VNS implantation 
(Table 5-5). We also found a significant difference in division index between time 
and condition for CD4+ CD25+ cells and Tregs (Table 5-6). Subsequent T-test 
comparisons revealed a significant reduction in Treg function up to 6 months after 
VNS implantation (Table 5-7). When comparing the proliferation index, there was 
a significant difference over time for CD8 T cells, CD25+ cells and Tregs (Table 
5-8) and paired T test comparisons revealed a significant reduction in Treg 
proliferation at 6 months in response to aCD3 (Table 5-9). Taken together, Treg 
function in response to anti-CD3 and SEB were blunted following VNS 
stimulation. These findings contradict the increase in Treg frequency observed 
on the day of blood sampling. Cell division is only one aspect of function, and the 
observed changes in Treg function warrants further investigations into other 
aspects of Treg function following treatment with VNS. 
 Cytokine Array 
A significant reduction in the relative expressions of BDNF, FGF-7, FGF-9, IL-1α, 
IL-1β, and MDC were identified following cytokine arrays from 4 patients prior to 
and 3 months following VNS implantation. A reduction in TNF-α was also 
detected and approaching statistical significance.  
Although the role of BDNF in inflammation is unknown, it role in depression has 
been heavily investigated. Meta-analysis of 11 studies correlated decreased 
concentrations of serum BDNF with major depression (Sen, Duman and 
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Sanacora, 2008), and <2.3 ng/ml BDNF may also be associated with OCD, 
anxiety (Wang et al., 2015) and schizophrenia (Qin et al., 2017). 
FGF-7 and FGF-9 are fibroblast growth factors for skin (Rubin et al., 1989) and 
blood vessels (Singla and Wang, 2016). Studies have investigated its roles in 
differentiation of epithelial cells during development (Belleudi et al., 2014), 
controlling proliferation of epithelial cells in the GI tract (Playford et al., 1998), 
wound healing (Marti et al., 2008; Zheng et al., 2014). 
IL-1α and IL-1β are pro-inflammatory cytokines which activate IL-1 receptors to 
upregulate inflammatory pathways (England et al., 2014; Schett, Dayer and 
Manger, 2015). While IL-1α is released from necrotic cells and act as alarmins 
(Kim et al., 2013; England et al., 2014), IL-1β is synthesised and secreted by cells 
of the innate immune system in response to apoptotic signals (England et al., 
2014). 
MDC is highly expressed by macrophages and dendritic cells with chemokine 
functions for dendritic cells, activated NK cells (Godiska et al., 1997), and T helper 
2 lymphocytes (Andrew et al., 1998) via activation of C-C chemokine receptor 
type 4 (CCR4) receptors (Imai et al., 1998). 
Although other groups have investigated changes in plasma cytokine levels 
following VNS treatment in patients, the effects of VNS on cytokine profile are 
unclear. One study reported a significant reduction in IL-1β (Koopman et al., 
2016), IL-6, and TNF-α (Koopman et al., 2016), while another study reports 
significant increase in IL-6, TGF-β and TNF-α (Corcoran et al., 2005). Three other 
studies did not find significant changes in cytokine levels in adults (Barone et al., 
2007; Majoie et al., 2011) or children (Aalbers et al., 2012) following VNS 
treatment. One limitation of cytokine arrays used in the current study is that it 
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provides relative and not absolute change in cytokine levels thus additional 
assays are required to deduce the concentration of cytokines. This would allow 
direct comparison with the studies above which have investigated changes in 
cytokine concentration. 
In summary, this study identified changes in the frequency for monocytes and 
CD25+ and CD4+ CD25+ cells with a trend in increasing Tregs. However, the 
functional capacity of Tregs in response to anti-CD3 antibodies may be reduced. 
Additional functional tests to assess the effects of VNS on Tregs are necessary. 
Furthermore, we identify changes in BDNF, FGF-7, FGF-9, and MDC, and future 
studies quantifying the expression of these cytokines with larger sample sizes are 
needed to validate this. 
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Chapter 6. Discussion 
The vagus nerve has many different functions (Section 1.1), however its 
underlying mechanisms remain unclear. Despite this, electrical stimulation of the 
vagus nerve has shown therapeutic benefits for conditions including: refractory 
epilepsy (Section 1.2.1), depression (Section 1.3.1), as well as inflammatory 
conditions including rheumatoid arthritis, stroke, and inflammatory 
gastrointestinal diseases (Section 1.5.3.3). This thesis aimed to explore 
additional effects of VNS treatment on mood, HRV, and inflammation to gain a 
deeper understanding behind the mechanisms of VNS, and to identify potential 
biomarkers for optimising treatment and to act as surrogate clinical endpoints.  
The key findings from this thesis were: 
• VNS may reduce perceived stress. 
• HRV reduces HF power which suggests a reduced sympathetic tone. 
However, this was not associated with the other beneficial effects of VNS 
observed in this study. 
• While increases in Treg frequency from fresh blood suggests promotion of 
immune tolerance, Tregs also displayed reduced function suggesting 
reduction in immune tolerance. 
• Cytokine array analysis identified significant changes in: BDNF, FGF-7, 
FGF-9, IL-1α, IL-1β, and MDC following VNS treatment.  
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 Combinatory Effects of VNS 
The vagus nerve interacts with many systems including the HPA-axis, 
neuroendocrine system, and immune system but much of the underlying 
mechanisms remain unknown. Interactions between these systems could 
potentially orchestrate complex responses and VNS may produce equally 
complex effects which may be difficult to isolate and study.  
For example, psychological stress can be a major factor for some diseases 
(Kendler, Karkowski and Prescott, 1999; Hammen, 2005; Booth et al., 2015; 
Targownik et al., 2015) with physiological responses including stress hormone 
production via the HPA-axis which may exacerbate disease through a positive-
feedback loop (Tsigos and Chrousos, 2002). In Chapter 3, we report a trend in 
reducing perceived stress 6 months following VNS implantation. Although no 
studies have previously reported changes in perceived stress following VNS, this 
finding is in line with the reduction in plasma cortisol levels in refractory epilepsy 
patients following VNS treatment (Majoie et al., 2011). The interaction between 
stress and VNS is currently unknown, however the innervation of vagus afferents 
to the hypothalamus via the NTS suggests a potential mechanism for the vagus 
nerve to modulate the HPA-axis. Therefore, VNS may have the potential to treat 
stress disorders through modulation of the HPA axis. Additional tools to monitor 
both perceived and physiological stress, as well as larger and longer studies will 
be required to confirm the therapeutic effects of VNS on stress. 
The HPA axis is able to exert cardiac effects including altering HRV (Thayer and 
Sternberg, 2006). Measures of HRV can be used as an indicator of the body’s 
ability to self-regulate physiological functions and autonomic tone (McCraty and 
Shaffer, 2015) and therefore may serve as aa non-invasive biomarker. In 
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Chapter 4, a significant reduction in HF relative power was found 6-months after 
VNS implantation but did not correlate to other measures tested in this thesis. As 
discussed in Section 4.4, While changes in HF power have been observed 
previously in other studies (Libbus et al., 2015; Liu et al., 2017), LF and HF 
measures of HRV do not correlate linearly to autonomic activity and cannot be 
used to infer autonomic tone (Billman, 2013). Despite this, such measures of HRV 
could still be relevant as biomarkers such as predicting response to VNS 
treatment in refractory epilepsy patients (Liu et al., 2017). 
Five-minute ECG recordings were used in the current study in a similar fashion 
to the study by Ponnusamy and colleagues (Ponnusamy, Marques and Reuber, 
2012). However, short ECG recordings may not be suitable for monitoring 
changes in HRV following VNS treatment due to influence from circadian effects. 
Future studies deploying 24-hour ambulatory ECGs would exclude circadian 
effects on HRV. Additionally, following patients for up to 2 years post-VNS 
implantation may allow the identification of trends between HRV and changes in 
mood or immune system once a therapeutic level of stimulation for reducing 
seizure frequency has been achieved. 
The underlying mechanisms for the anti-inflammatory reflex was first 
hypothesised by Tracey and colleagues (Section 1.5.3.1). However, this does 
not explain how VNS exerts its anti-inflammatory effect systemically as observed 
in rat studies. In Chapter 5, immune cell frequencies and functions were 
observed before and after VNS implantation. A trend in increasing Treg frequency 
was observed and is in line with the increase in Tregs found in rat following VNS 
treatment (Morishita et al., 2015). However, the current study also found a 
significant reduction in Treg function in response to anti-CD3 antibody. While the 
interactions between VNS and Tregs remain unknown, additional assays 
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assessing functional changes in Tregs would aid in the understanding between 
VNS and Tregs. 
To our knowledge, no studies have reported the use of cytokine arrays to 
investigate the effects of VNS. In Chapter 5, cytokine array analysis of fresh 
plasma samples before and 3 months following VNS implantation identified 
significant reductions in the expression for BDNF, FGF-7, FGF-9, IL-1α, IL-1β, 
and MDC.  
While the role of BDNF in inflammation is currently unknown, its mechanism for 
its anti-depressive effects are known (Duman and Monteggia, 2006), and 
enhancing BDNF concentrations and activity have been an aim for treating 
depression. Most studies on FGF-7 and FGF-9 have investigated their roles in 
differentiation of epithelial cells (Playford et al., 1998; Belleudi et al., 2014) and 
wound healing (Marti et al., 2008; Zheng et al., 2014). IL-1α and IL-1β are 
classical markers of inflammation which upregulate inflammatory pathways 
(England et al., 2014; Schett, Dayer and Manger, 2015). Macrophage derived 
chemokines MDCs (aka CCL22) have been reported to play a role in the 
recruitment of Tregs to inflamed tissue and tumours (Nishikawa and Sakaguchi, 
2010). While the normal role of Tregs is to resolve inflammation, in the context of 
tumour immunity, it may act to promote immune tolerance and allow the 
proliferation of cancer cells (Li et al., 2013).  
Additional studies are required to validate these findings and quantify the 
changes in expression of these cytokines. This would provide us with a greater 
understanding behind the mechanism and effects of VNS. 
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 General Limitations 
As stated in the introduction (Section 1.6), we were limited by the heterogenous 
patient population with different co-morbidities and patients taking a combination 
of many medications. Although some patients took medication with anti-
inflammatory effects, these were not prescribed routinely and thus were not 
excluded from the study (Appendix Section 8.3). The study was also restricted 
to a small sample size as only patients receiving VNS implantation at RHH were 
approached and recruited. A multi-centre approach in the future would increase 
sample size to aid the validation of findings from the current study. 
Data was collected up to 6-months following VNS implantation in the current 
study. This duration may not have been long enough as it can take up to 2 years 
to optimise device settings to achieve a meaningful reduction in seizure 
frequency. By extending the study to collect data from patients at 2 years post-
VNS implantation, further analysis comparing changes in mood, HRV and 
immune system between responders and non-responders to VNS treatment will 
be possible. 
 Alternative Methods of VNS 
In addition to overcoming the limitations in study above, alternative methods of 
VNS could potentially be used to enhance research in VNS. Implantable VNS 
currently requires surgical intervention and therefore its associated surgical risks. 
This may pose unnecessary risks for the majority of refractory epilepsy patients 
who do not respond to VNS treatment. To address this, transcutaneous forms of 
VNS have been explored and offered as an alternative to invasive VNS. 
Transcutaneous VNS (tVNS) does not require surgical intervention and treatment 
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can be halted easily should the patient not respond to tVNS treatment. 
Furthermore, as the device is not implanted, stimulation settings may be adjusted 
easily without hospital visits. Currently there are two forms of tVNS available: 
Gammacore by Electrocore and NEMOS by Cerbomed, both of which are safe 
and well tolerated in patients (Figure 6-1). Gammacore is a handheld device to 
stimulate the cervical nerve and has been primarily used to treat headaches and 
migraines (Goadsby et al., 2014; Barbanti et al., 2015; Grazzi, Padovan and 
Barbanti, 2015; Nesbitt et al., 2015). The NEMOS system stimulates an auricular 
branch of the vagus nerve at the concha of the ear to produce anti-epileptic 
effects. Furthermore, fMRI analysis has shown its ability to stimulate the NTS in 
a similar fashion to invasive VNS (Dietrich et al., 2008; Frangos, Ellrich and 
Komisaruk, 2014). The therapeutic potential of tVNS is yet to be fully explored 
and could be used in future studies to examine its effects on stress, and explore 
the underlying mechanisms in the relationship between VNS and Tregs. 
 
Figure 6-1 commercially available tVNS devices 
(A) Gammacore stimulator manufactured by Electrocore (www.gammacore.co.uk), (B) NEMOS 
stimulator manufactured by Cerbomed (www.nemos.uk.com). 
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 Concluding Remarks 
This thesis explored the effects of VNS on mood, HRV, and immune system in 
patients with refractory epilepsy and identified potential avenues to further VNS 
research. First, we observed a trend in reducing perceived stress following VNS 
implantation suggesting its therapeutic potential for treating stress disorders. 
Secondly, we observed a significant increase in Treg frequency but also found a 
reduction in Treg function 6 months following VNS implantation. Further work is 
required to study the underlying mechanisms of VNS on Treg function. Lastly, we 
identified significant reductions in expression of BDNF, FGF-7, FGF-9, IL-1α, 
IL-1β, and MDC 3 months following VNS implantation, with future work being 
required to validate and quantify the expression of these cytokines.  
The interactions between the vagus nerve and other systems is complex. While 
much of the therapeutic applications and mechanisms of VNS remain to be 
explored, it has the potential to benefit patients who may otherwise remain 
refractory to treatment. 
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 Volunteer consent form template 
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 Patient information sheet 
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 Patient consent form template 
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 Patient information 
Patient ID 011 Age  22 Gender  Male 
Diagnosis Refractory epilepsy 
List of medications prescribed 
during study 
Use and anti-inflammatory effects if any 
Beclometasone Treatment for oral ulcertaion / asthma / prophylaxis 
Carbamazepine AED 
Epipen  
Prescribed for food allergy – no cases of allergy 
documented during period of study 
Lamotrigine AED 
Salbutamol sulfate * Bronchospasm treatment  
 
Patient ID 014 Age  46 Gender  Female 
Diagnosis Refractory epilepsy 
List of medications prescribed 
during study 
Use and anti-inflammatory effects if any 
Aciclovir Treatment for suspected shingles between 16-21/6/16 
Mizolastine* Anti-inflammatory (anti-histamine) drug for hayfever 
Omeprazole 
Typically used to prevent/treat stomach ulcers and 
treatment for indigestion and acid reflux. 
OTC cranberry remedies for 
cystitis symptoms 
Cystitis symptom relief 
Phenobarbitol AED 
Zapain Contains paracetamol and codeine phosphate.  
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Patient ID 016 Age  25 Gender  Male 
Diagnosis Medically refractory focal epilepsy with aphasia, previous multiple subpial 
transections left temporal love and left MTS 
List of medications prescribed 
during study 
Use and anti-inflammatory effects if any 
Clobazam AED 
Flucloxacillin * Antibiotic, 1 dose only 
Keppra AED 
Midazolam AED 
Nitrofurantoin* Antibiotic, 1 dose only 
Rufinamide  Anticonvulsant medication, 3 doses (not routine) 
 
Patient ID 022 Age  42 Gender  Female 
Diagnosis Focal temporal lobe epilepsy 
List of medications prescribed 
during study 
Use and anti-inflammatory effects if any 
Alzain (brand of pregabalin) Treatment for epilepsy, neuropathic pain, and 
generalised anxiety disorder 
Ibuprofen* NSAID 
Perampanel AED 
Pregabalin AED 
Zonegran AED 
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 Copies of Questionnaires 
 Liverpool Seizure Severity Scale 2.0 (LSSS) 
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 Neurological Disorders Depression Inventory for 
Epilepsy (NDDI-E) 
Background: 
Depression is a common disorder in epilepsy but is not routinely assessed in 
clinics. The Neurological disorders depression inventory for epilepsy (NDDI-E) is 
used to rapid screening of major depression in people with epilepsy. Symptoms 
of major depression in this test is able to differentiate that from adverse effects of 
AED. The baseline of a score <15 was determined and verified from 229 patients. 
An NDDI-E score of more than 15 had a specificity of 90%, sensitivity of 81%, 
and positive predictive value of 0·62 for the identification of major depression. 
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 General Anxiety Disorder Assessment (GAD-7) 
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 Fatigue Assessment Scale (FAS) 
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 Perceived Stress Scale (PSS) 
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 Figures 
 
Appendix Figure 1 Example of automated HRV analysis by Kubios HRV 
HRV measurements for patient 014 prior to VNS implantation 
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Appendix Figure 2 Fluorescence emission of fluorophores and dyes selected for flow 
cytometry 
Fluorophore and dye combinations were selected using the Fluorescence 
SpectraViewer available online (https://www.thermofisher.com/uk/en/home/life-
science/cell-analysis/labeling-chemistry/fluorescence-spectraviewer.html). The 
LSRII flow cytometer has 4 excitation lasers at (A) 355nm, (B) 405nm, (C) 488nm, 
and (D) 633nm with a selection of emission filters for each laser. Combinations 
used were chosen to have a relatively high intensity of emission, peak of emission 
passing through emission filter, and the least amount of overlapping fluorescence 
emission for each excitation laser.   
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Appendix Figure 2 (cont’d) Fluorescence emission of fluorophores and dyes selected for 
flow cytometry 
Fluorophore and dye combinations were selected using the Fluorescence 
SpectraViewer available online (https://www.thermofisher.com/uk/en/home/life-
science/cell-analysis/labeling-chemistry/fluorescence-spectraviewer.html). The 
LSRII flow cytometer has 4 excitation lasers at (A) 355nm, (B) 405nm, (C) 488nm, 
and (D) 633nm with a selection of emission filters for each laser. Combinations 
used were chosen to have a relatively high intensity of emission, peak of emission 
passing through emission filter, and the least amount of overlapping fluorescence 
emission for each excitation laser.   
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 Tables 
Appendix Table 1 Summary of HRV parameters 
 Measure Units Description 
T
im
e
-D
o
m
a
in
 
RR [ms] The mean of RR intervals 
STD RR (SDNN) [ms] Standard deviation of RR intervals 
HR  [1/min] The mean of heart rate 
STD HR [1/min] Standard deviation of instantaneous heart rate values 
RMSSD [ms] Square root of the mean squared differences between 
successive RR intervals 
NN50  Number of successive RR interval pairs that differ more 
than 50 ms 
pNN50 [%] NN50 divided by the total number of RR intervals 
HRV Triangular 
index 
 The integral of the RR interval histogram divided by the 
height of the histogram 
TINN [ms] Baseline width of the RR interval histogram 
F
re
q
u
e
n
c
y
-D
o
m
a
in
 
Peak frequency [Hz] VLF, LF, and HF band peak frequencies 
Absolute power [ms2] Absolute powers of VLF, LF, and HF bands 
Relative power [%] Relative powers of VLF, LF, and HF bands 
VLF [%] = VLF [ms2] / total power [ms2] × 100% 
LF [%] = LF [ms2] / total power [ms2] × 100% 
HF [%] = HF [ms2] / total power [ms2] × 100% 
Normalised power [n.u.] Powers of LF and HF bands in normalized units 
LF [n.u.] = LF [ms2] / (total power [ms2] – VLF [ms2]) 
HF [n.u.] = HF [ms2] / (total power [ms2] – VLF [ms2]) 
LF/HF  Ratio between LF and HF band powers 
N
o
n
-l
in
e
a
r 
SD1, SD2 [ms] The standard deviation of the Poincaré plot perpendicular 
to (SD1) and along (SD2) the line-of-identity 
ApEn  Approximate entropy 
SampEn  Sample entropy 
D2  Correlation dimension 
DFA  Detrended fluctuation analysis: 
α1  Short term fluctuation slope 
α2  Long term fluctuation slope 
RPA  Recurrence plot analysis: 
Lmean [beats] Mean line length 
Lmax [beats] Maximum line length 
REC [%] Recurrence rate 
DET [%] Determinism 
ShanEn  Shannon entropy 
Table taken from Kubios HRV version 2.2 User’s guide 2014. 
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Appendix Table 2 Sample size calculations for questionnaires 
Questionnaire 
Sample size required for 
when α=0.05, 1-β=0.8 
3M – PS 6M – PS 
LSSS 32 118 
NDDI-E 1030 1067 
GAD-7 63 182 
FAS 45 78 
PSS 29 20 
 
Appendix Table 3 Sample size calculations for measures of HRV 
Measure of HRV 
Sample size required when 
α=0.05, 1-β=0.8 
3M – PS 6M – PS 
Mean (ms) 33 18 
SDNN (ms) 187 19.62 
Mean HR (bpm) 475 20 
Stdev HR (bpm) 41 1023 
RMSSD (ms) 154 1049 
NN50 284 474 
pNN50 (%) 299 441 
HRV Triangular Index 86 6923 
TINN (ms) 109 10391 
LF Peak Frequency (Hz) 22 53 
LF Absolute Power (ms2) 307 40 
LF Relative Power (%) 69 13 
LF Normalised Power (n.u.) 36 1526 
HF Peak Frequency (Hz) 45 28 
HF Absolute Power (ms2) 1313 150 
HF Relative Power (%) 4659 6 
HF Normalised Power (n.u.) 45 112 
LF/HF Ratio 409 275 
SD1 (ms) 1228 582 
SD2 (ms) 399 52384 
Approx Entropy 40 44 
Sample Entropy 3423 153 
D2 355 1002 
DFA α1 1125 406 
DFA α2 288 665 
Lmean (beats) 192 1209 
Lmax (beats) 14342 17 
REC (%) 454 375 
DET (%) 168 53 
Shannon Entropy 117 118 
MSE min 24 41 
MSE max 86 2247 
CSI 31159 22 
CVI 433 93 
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Appendix Table 4 Full HRV results 
 
One-way 
ANOVA 
p value 
(n=7) 
3M – PS (n=11) 6M – PS (n=8) 
Mean 
diff. 
SD of 
diff. 
T test 
p 
value 
Mean 
diff. 
SD of 
diff. 
T test 
p 
value 
Mean (ms) 0.2626 -34.07 76.53 0.1706 -50.12 80.53 0.1217 
SDNN (ms) 0.6438 +2.54 13.91 0.5583 +1.164 19.62 0.8715 
Mean HR (bpm) 0.211 +1.162 10.17 0.7127 +3.885 6.628 0.1413 
STD HR (bpm) 0.4489 +0.5203 1.31 0.2171 +0.1164 1.496 0.8321 
RMSSD (ms) 0.7335 -2.238 11.11 0.519 -1.214 15.8 0.8341 
NN50 0.7172 -2.727 18.42 0.6339 +2.875 25.13 0.7557 
pNN50 (%) 0.7291 -1.464 10.15 0.6426 +1.557 13.12 0.7468 
HRV Triangular 
Index 
0.3912 -1.022 3.759 0.3882 -0.0931 3.115 0.935 
TINN (ms) 0.6443 +17.73 73.67 0.4433 +1.875 76.86 0.9469 
LF Peak 
Frequency (Hz) 
0.3571 -5.014 8.973 0.0936 -1.686 4.83 0.3563 
LF Absolute 
Power (ms2) 
0.4509 -51.36 360.6 0.6468 -130.5 324 0.2921 
LF Relative 
Power (%) 
0.235 +6.625 21.85 0.3383 -8.021 10.8 0.0738 
LF Normalised 
Power (n.u.) 
0.7876 +13.57 31.92 0.1891 +0.7669 12.04 0.8622 
HF Peak 
Frequency (Hz) 
0.2545 -0.1955 0.5189 0.2398 -0.0477 0.09748 0.2088 
HF Absolute 
Power (ms2) 
0.8325 -16.13 234.9 0.8244 -60.39 295.5 0.5814 
HF Relative 
Power (%) 
0.3939 -0.4536 12.45 0.9062 -6.381 5.149 0.0099 
HF Normalised 
Power (n.u.) 
0.7021 -38.88 102.8 0.238 -3.287 13.86 0.5237 
LF/HF Ratio 0.6487 +0.2188 1.775 0.6911 +0.1161 0.7713 0.6832 
SD1 (ms) 0.8766 -0.4865 6.852 0.8186 -1.157 11.21 0.7787 
SD2 (ms) 0.6896 +1.9 15.23 0.6877 +0.2854 26.27 0.9763 
Approx 
Entropy 
0.4676 +0.0465 0.1155 0.2117 +0.0489 0.1277 0.3148 
Sample 
Entropy 
0.5578 -0.0186 0.438 0.8907 -0.0830 0.4099 0.5849 
D2 0.5841 +0.1953 1.475 0.6699 +0.1389 1.767 0.8305 
DFA α1 0.8643 +0.0188 0.2529 0.8107 +0.0268 0.2166 0.7367 
DFA α2 0.6669 -0.0437 0.2973 0.6366 +0.0339 0.3516 0.7927 
Lmean (beats) 0.2241 -0.8388 4.653 0.5632 +0.4657 6.507 0.8453 
Lmax (beats) 0.5053 +2 96.32 0.9465 +22.25 35.29 0.1177 
REC (%) 0.2406 -1.223 10.46 0.7064 +1.657 12.87 0.7264 
DET (%) 0.461 -0.3643 1.886 0.5362 +0.6005 1.722 0.3567 
Shannon 
Entropy 
0.2408 -0.0969 0.418 0.4599 +0.0993 0.4299 0.5345 
MSE min 0.2154 +0.2184 0.4082 0.1064 +0.1642 0.4134 0.2982 
MSE max 0.9019 +0.188 0.6915 0.3883 +0.0363 0.691 0.8862 
CSI 0.3974 -0.0022 0.1593 0.9637 -0.0580 0.1054 0.1638 
CVI 0.9474 +0.0294 0.2456 0.6996 -0.1459 0.56 0.4852 
Note: P values for ANOVA and paired T test was Tukey-corrected 
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Appendix Table 5 Full cytokine array results 
Cytokine 
Mean 
change 
relative 
to PS 
SD of 
mean 
change 
Paired 
T test 
p value 
 
Cytokine 
Mean 
change 
relative 
to PS 
SD of 
mean 
change 
Paired 
T test 
p value 
ENA-78 -35.03% 42% 0.1139 VEGF -33.27% 49% 0.1132 
G-CSF -39.80% 42% 0.1390 PDGF BB -27.66% 65% 0.1646 
GM-CSF -41.00% 42% 0.2604 Leptin -61.64% 85% 0.1581 
GRO -42.65% 45% 0.1887 BDNF -56.01% 35% 0.0322 
GRO-alpha +8.36% 82% 0.4709 BLC -28.41% 59% 0.1572 
I-309 -29.93% 49% 0.1455 CCL23 -38.05% 49% 0.0673 
IL-1 alpha -48.32% 34% 0.0160 Eotaxin 1 -0.18% 80% 0.3512 
IL-1 beta -46.78% 32% 0.0054 Eotaxin 2 -39.57% 50% 0.1258 
IL-1 -14.09% 63% 0.2555 Eotaxin 3 -19.76% 48% 0.3947 
IL-3 -31.61% 57% 0.1099 FGF 4 -20.86% 61% 0.1820 
IL-4 -15.59% 58% 0.2871 FGF 6 -25.44% 54% 0.1629 
IL-5 -22.01% 53% 0.4420 FGF 7 -46.37% 33% 0.0380 
IL-6 -2.87% 81% 0.3957 FGF 9 -50.43% 34% 0.0293 
IL-7 -32.61% 42% 0.1193 Flt-3 Ligand -27.45% 59% 0.1340 
IL-8 -51.70% 41% 0.1875 Fractalkine -47.25% 50% 0.2526 
IL-10 -40.93% 55% 0.1985 GCP-2 -20.42% 58% 0.1549 
IL-12 p40/70 -22.31% 58% 0.2105 GDNF -0.66% 115% 0.2002 
IL-13 -35.23% 50% 0.1484 HGF -19.69% 82% 0.1609 
IL-15 -22.24% 69% 0.1233 IGFBP1 -30.54% 64% 0.1816 
IFN gamma -36.26% 39% 0.0784 IGFBP2 -17.22% 61% 0.3207 
MCP-1 -30.42% 60% 0.1148 IGFBP3 -25.52% 65% 0.1133 
MCP-2 -8.93% 69% 0.2348 IGFBP4 -10.60% 69% 0.2301 
MCP-3 -39.23% 40% 0.0731 IL-16 -41.09% 46% 0.0672 
M-CSF -34.86% 54% 0.1087 IP-10 -12.39% 68% 0.2141 
MDC -38.52% 40% 0.0491 LIF -34.92% 57% 0.1067 
MIG -35.02% 41% 0.0726 LIGHT -24.81% 67% 0.2281 
MIP-1 beta -38.92% 49% 0.2388 MCP-4 +9.57% 94% 0.3410 
MIP-1 delta -20.47% 65% 0.2213 MIF -17.24% 69% 0.2270 
RANTES -88.02% 67% 0.0621 MIP-3 alpha -9.46% 71% 0.3061 
SCF -32.41% 48% 0.1152 NAP-2 -8.44% 103% 0.2761 
SDF-1 -42.62% 41% 0.0758 NT-3 -31.17% 49% 0.1758 
TARC -48.17% 39% 0.0707 NT-4 -27.92% 63% 0.1794 
TGF-beta 1 -55.94% 41% 0.0785 OPN -8.79% 76% 0.3189 
TNF alpha -55.71% 39% 0.0504 OPG -22.45% 65% 0.2227 
TNF beta -41.47% 44% 0.0645 PARC -16.06% 71% 0.1829 
EGF -18.81% 90% 0.1204 PLGF -42.28% 55% 0.0892 
IGF-1 -20.12% 50% 0.2976 TGF-beta 2 -40.60% 55% 0.0804 
ANG -9.02% 64% 0.2807 TGF-beta 3 -18.61% 63% 0.2374 
OSM -35.40% 53% 0.1764 TIMP-1 -1.03% 102% 0.2679 
THPO -39.79% 42% 0.0936 TIMP-2 -13.98% 97% 0.1878 
Note: P values for paired T test were Bonferroni corrected. 
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